Availability of pulmonary function tests (PFTs – spirometry, diffusing capacity of the lungs for carbon monoxide [DLCO], +/- arterial blood gases) within 90 days prior to registration; patients with tracheotomy, etc, who are physically unable to perform PFTs are potentially still eligible if a study credentialed thoracic surgeon documents that the patient’s health characteristics would otherwise have been acceptable for eligibility as a high risk but nonetheless operable patient (in particular be eligible for sublobar resection)Xx_NEWLINE_xXPatient at high-risk for surgery by meeting a minimum of one major criteria or two minor criteria as described below:\r\n* Major criteria\r\n** Forced expiratory volume in 1 second (FEV1) =< 50% predicted\r\n** DLCO =< 50% predicted\r\n* Minor criteria\r\n** FEV1 51-60% predicted\r\n** DLCO 51-60% predicted\r\n** Pulmonary hypertension (defined as a pulmonary artery systolic pressure greater than 40 mm Hg) as estimated by echocardiography or right heart catheterization\r\n** Poor left ventricular function (defined as an ejection fraction of 40% or less)\r\n** Resting or exercise arterial partial pressure of oxygen (pO2) =< 55 mm Hg or peripheral capillary oxygen saturation (SpO2) =< 88%\r\n** Partial pressure of carbon dioxide (pCO2) > 45 mm Hg\r\n** Modified medical research council (MMRC) dyspnea scale >= 3\r\n** Study credentialed thoracic surgeon believes the patient is potentially operable but that a lobectomy or pneumonectomy would be poorly tolerated by the patient for tangible or intangible reasonsXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from Hodgkin lymphoma (HL)Xx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)Xx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)Xx_NEWLINE_xXForced vital capacity (FVC) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)Xx_NEWLINE_xXPatients must have postoperative predicted carbon monoxide diffusing capability (DLCO) > 35% prior to surgery obtained within 28 days prior to step 2 registrationXx_NEWLINE_xXPatients must have pulmonary function sufficient to receive bleomycin, with normal lung expansion, absence of crackles on auscultation, and normal carbon monoxide diffusion (DLCO), defined as greater than 80% predictedXx_NEWLINE_xXNormal pulmonary function tests (including diffusion capacity of the lung for carbon monoxide [DLCO]) if there is clinical indication for determination (e.g. dyspnea at rest, known requirement for supplemental oxygen); for patients who do not have respiratory symptoms or requirement for supplemental oxygen, pulmonary function tests (PFTs) are NOT requiredXx_NEWLINE_xXDLCO/VA and FEV1 ? 50% of predicted on PFTs.Xx_NEWLINE_xXPatients must have a forced expiratory volume in one second (FEV-1) and diffusing capacity of the lung for carbon monoxide (DLCO) > 50% predictedXx_NEWLINE_xXCorrected diffusion capacity of carbon monoxide (DLCO) < 40%, total lung capacity (TLC) < 40%, forced expiratory volume in one second (FEV1) < 40% and/or receiving supplementary continuous oxygenXx_NEWLINE_xXForced expiratory volume in one second (FEV1) and carbon monoxide diffusion capacity (DLCO) (adjusted for hemoglobin [Hb]) >= 50% adjustedXx_NEWLINE_xXParticipants with significant symptomatic deterioration of lung function; if clinically indicated, pulmonary function tests including measures of predicted lung volumes, carbon monoxide diffusing capability test (DLco), oxygen (O2) saturation at rest on room air should be considered to exclude restrictive pulmonary disease, pneumonitis or pulmonary infiltratesXx_NEWLINE_xXForced expiratory volume in 1 second (FEV-1) or diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) >= 50% predicted; timeline: within 4 weeks prior to enrollmentXx_NEWLINE_xXPulmonary function forced expiratory volume in 1 second (FEV1) >= 50% of predictedXx_NEWLINE_xXNormal pulmonary functions tests (including carbon monoxide diffusing capability test [DLCO]) if there is a clinical indication for determination (dyspnea at rest, known requirement for supplemental oxygen); for subjects who do not have respiratory symptoms (no dyspnea at rest, oxygen [O2] saturation [sat] >= 93% on room air), full pulmonary function tests (PFTs) are NOT requiredXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >= 40% of predicted; or in pediatric patients, if unable to perform pulmonary function tests due to young age, oxygen saturation > 92% on room airXx_NEWLINE_xXPulmonary function tests within 6 months of study enrollment must have forced expiratory volume in 1 second (FEV1) >= 1.2 L and diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% of predicted; patients with FEV1 of < 1.2 L but a predicted value of >= 40% may be eligible after review of the case by the study radiation primary investigator (PI) or his designeeXx_NEWLINE_xXPulmonary function (FVC, FEV1 and corrected DLCO) > 50% predicted.Xx_NEWLINE_xXChronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) is less than (<) 50 % of predicted normalXx_NEWLINE_xXSubject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal\r\n* Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50% of predicted normalXx_NEWLINE_xXCarbon monoxide diffusing capability (DLCO) > 60% predicted (in children, oxygen [O2] saturation > 92% on room air)Xx_NEWLINE_xXParticipants with unilateral pleural effusion are eligible if they fulfill both of the following: (a) New York Heart Association (NYHA) Class 1; (b) Global initiative for obstructive lung disease (GOLD) test level 1 (forced expiratory volume in 1 second [FEV1]/ forced vital capacity [FVC] less than [<] 0.7 and FEV1 greater than or equal to [>=] 80 percent [%] predicted after inhaled bronchodilator)Xx_NEWLINE_xXSubjects must have adequate lung function to permit surgical resection determined by pre-enrollment pulmonary function tests to include diffusion capacity of the lung for carbon monoxide (DLCO) as follows:\r\n* DLCO >= 70% predicted OR DLCO < 70% but >= 55% with an oxygen consumption (VO2) max >= 10 L/min/kg (assessed by cardiopulmonary exercise testing) or 6 minute walk test >= 500 meters\r\n* Subjects with a DLCO < 55% are excluded from this study\r\n* Subjects must have a baseline oxygen (O2) saturation by pulse oximetry that is >= 92% both at rest and while walking, off supplemental oxygenXx_NEWLINE_xXPatients with Adequate Physical Function as Measured by: a. Cardiac: Left ventricular ejection fraction at rest must be greater than or equal to 40%, or shortening fraction less than 25%; b. Hepatic: Bilirubin less than or equal to 2.5 mg/dL, except for patients with Gilbert's syndrome or hemolysis. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and Alkaline Phosphatase less than 5 x upper limit of normal; c. Renal: Serum creatinine within normal range, or if serum creatinine outside normal range, then renal function (measured or estimated creatinine clearance or GFR)greater than 40 mL/min/1.73m^; d. Pulmonary: Diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC) greater than 50% predicted;Xx_NEWLINE_xXPulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) ? 40% (adjusted for hemoglobin) and forced expiratory volume in one second (FEV1) ? 50%Xx_NEWLINE_xXParticipant has diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) ? 50% predicted and/or forced expiratory volume in 1 second (FEV1) ? 50% predicted.Xx_NEWLINE_xXPulmonary: For patients > 13.0 years of age: Diffusing capacity of the lung for carbon monoxide (DLCO) (corrected/adjusted for hemoglobin) > 40% and forced expiratory volume in one second (FEV1) > 50% predicted (without administration of bronchodilator) and forced vital capacity (FVC) > 50% predicted. For patients < 13.0 years of age unable to perform pulmonary function tests (PFT) due to age or developmental ability: (1) no evidence of dyspnea at rest and (2) no need for supplemental oxygen and (3) O2 saturation > 92% on room air at sea level (with lower levels allowed at higher elevations per established center standard of care (e.g., Utah, 4,200 feet above sea level, does not give supplemental oxygen unless below 90%)).Xx_NEWLINE_xXTREATMENT INCLUSION: Adequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) ? 50% of expected corrected for hemoglobinXx_NEWLINE_xXPFTs including forced expiratory volume in 1 second (FEV1) within 26 weeks prior to registration; for FEV1, the best value obtained pre- or post-bronchodilator must be >= 0.8 liters/second or >= 50% predictedXx_NEWLINE_xXAll patients must have an forced expiratory volume in 1 second (FEV1) >= 700ccXx_NEWLINE_xXAll patients must have a carbon monoxide diffusing capability test (DLCO) >= 5.5 m/min/mmHgXx_NEWLINE_xXPulmonary function tests: diffusing capacity of the lungs for carbon monoxide (DLco) (corrected for hemoglobin) and forced expiratory volume in 1 second (FEV1) >= 50% of predicted for the MAC arm, >= 40% of predicted for the RIC and RIC-MMF arm, and >= 30% predicted for the IOC arm; or in pediatric patients, if unable to perform pulmonary function tests, there should be no evidence of dyspnea at rest, no requirement for supplemental oxygen, and oxygen saturation > 92% on room air; calculations will be based on the Unites States of America National Institutes of Health (USA-ITS-NIH) referenceXx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) >= 50%Xx_NEWLINE_xXForced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) >= 50% predictedXx_NEWLINE_xXPulmonary: FEV 1, FVC, DLCO (diffusion capacity) ? 50% predicted (corrected for hemoglobin)Xx_NEWLINE_xXDocumented diffusion capacity of the lung for carbon monoxide (DLCO) < 50% (if performed within 90 days of enrollment) or requirement for supplemental oxygenXx_NEWLINE_xXPatients without respiratory symptoms (e.g. dyspnea at rest, known requirement for supplemental oxygen therapy) and who have an oxygen saturation > 92% on room air, will be eligible; for patients not meeting this criteria, pulmonary function tests will be performed to confirm that the diffusion capacity of the lung for carbon monoxide (DLCO)/alveolar volume (VA)/Adj is 50% of the normal predicted value corrected for hemoglobin and alveolar volume in order to meet eligibility\r\n* (For children who are unable to cooperate for pulmonary function test [PFT]s, the criterion is: No evidence of dyspnea at rest, no exercise intolerance and no requirement for supplemental oxygen therapy)Xx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) corrected < 60%; patients who are unable to perform pulmonary function tests (for example, due to young age and/or developmental status) will be excluded if the oxygen (O2) saturation is < 92% on room airXx_NEWLINE_xXDLCO corrected < 50%; patients who are unable to perform pulmonary function tests (for example, due to young age and/or developmental status) will be excluded if the O2 saturation is < 92% on room air; patients with a DLCO 50-60% must also have a partial pressure of oxygen (pO2) of > 80 mmHgXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) > 65% of prediction for those patients with extensive pulmonary metastases or chronic pulmonary disease historyXx_NEWLINE_xXForced vital capacity (FVC) > 65% of prediction for those patients with extensive pulmonary metastases or chronic pulmonary disease historyXx_NEWLINE_xXDocumented forced expiratory volume in 1 second (FEV1) of less than or equal to 50% predicted in patients with clinical symptomatologyXx_NEWLINE_xXDocument forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 pack [pk]/year of smoking within the past 2 years).\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXForced expiratory volume in one second (FEV1) or diffusing capacity of the lung for carbon monoxide (DLCO) < 40% or need for use of supplemental oxygenXx_NEWLINE_xXDocumented forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 packs [pk]/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 2.0 liters or >= 75% of predicted for height and age; (pulmonary function tests (PFTs) are required for patients over 50 or with significant pulmonary or smoking history defined as > 20 pack years or history of chronic obstructive pulmonary disease [COPD]/emphysema)Xx_NEWLINE_xXDocumented forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 pack [pk]/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXPatients with impaired pulmonary function as evidenced by diffusion capacity of the lung for carbon monoxide (DLCO) < 50% of predicted (or, if unable to perform pulmonary function tests, then oxygen [O2] saturation < 92% on room air)Xx_NEWLINE_xXDiffusion capacity for carbon monoxide corrected (DLCOcorr) > 50% normal or a pediatric patient who is unable to perform pulmonary function tests (PFTs) but has adequate pulmonary functionXx_NEWLINE_xXTREATMENT WITH SJCAR19: Forced vital capacity (FVC) >= 50% of predicted value; or pulse oximetry >= 92% on room air if patient is unable to perform pulmonary function testingXx_NEWLINE_xXDocumented forced expiratory volume in one second (FEV1) =< 50% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (approximately 20 packs/year within the past 2 years).\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXPulmonary: Asymptomatic or if symptomatic, diffusion capacity of the lung for carbon monoxide (DLCO) > 50% of predicted (corrected for hemoglobin).Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) of < 50% predicted or carbon monoxide diffusing capacity (DLCO) (corrected) < 40% (patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing)Xx_NEWLINE_xXCarbon monoxide diffusing capacity (DLCO) and forced expiratory volume in 1 second (FEV1) > 50% predictedXx_NEWLINE_xXCarbon monoxide diffusing capacity (DLCO) 40% predicted.Xx_NEWLINE_xXKnown severe chronic obstructive pulmonary disease or asthma defined as forced expiratory volume (FEV1) in 1 second less than < 60% of expectedXx_NEWLINE_xXPulmonary function tests including diffusing capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in 1 second (FEV 1) and DLCO should be greater than 50% of predicted normal valueXx_NEWLINE_xXPulmonary function tests (spirometry) demonstrating forced expiratory value (FEV) 1 greater than 65% predicted or forced vital capacity (FVC) greater than 65% of predicted.Xx_NEWLINE_xXPulmonary function\r\n* Baseline oxygen saturation > 92% on room air at rest \r\n* Patients with respiratory symptoms must have a diffusing capacity of the lungs for carbon monoxide (DLCO)/adjusted > 45%; for children who are unable to cooperate for pulmonary function tests (PFTs) they must not have dyspnea at rest or known requirement for supplemental oxygenXx_NEWLINE_xXKnown chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume in 1 second [FEV1] < 50% of predicted normal), persistent asthma, or a history of poorly controlled asthma within the last 2 years (controlled intermittent asthma or controlled mild persistent asthma is allowed)Xx_NEWLINE_xXPulmonary function (spirometry and corrected diffusion capacity of the lung for carbon monoxide [DLCO]) >= 50% predicted.Xx_NEWLINE_xXCorrected diffusion capacity of the lung for carbon monoxide (DLCOc) >= 50%;Xx_NEWLINE_xXPatients who have obstructive or restrictive pulmonary disease and have a documented FEV1 (forced expiratory volume in 1 second) of ? 60%Xx_NEWLINE_xXDocumented forced expiratory volume-one second (FEV1) less than or equal to 50% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (approximately 20 packs/year within the past two years)\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide/alveolar volume ratio (DLCO/VA) and forced expiratory volume in 1 second (FEV1) >= 50% of predicted on pulmonary function tests (subjects must have pulmonary function tests performed to be eligible)Xx_NEWLINE_xXParticipant must be considered ineligible for induction therapy defined by the following: a. >= 75 years of age; or b. >= 18 to 74 years of age with at least one of the following comorbidities: i. Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or 3; ii. Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction <= 50% or chronic stable angina; iii. Diffusing capacity of the Lung for Carbon Monoxide (DLCO) <= 65% or Forced Expiratory Volume in 1 second (FEV1) <= 65%; iv. Creatinine clearance >= 30 mL/min to < 45 ml/min; v. Moderate hepatic impairment with total bilirubin > 1.5 to <= 3.0 × Upper Limit of Normal (ULN); vi. Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the AbbVie Therapeutic Medical Director during screening and before study enrollment.Xx_NEWLINE_xXHemoglobin-adjusted diffusing capacity of carbon monoxide (DLCO) of >= 45%Xx_NEWLINE_xXPulmonary function: Carbon monoxide diffusing capability (DLCOc) < 40% normalXx_NEWLINE_xXMajor organ dysfunction defined as:\r\n* Creatinine clearance < 20 ml/min\r\n* Significant hepatic dysfunction (serum glutamic-oxaloacetic transaminase [SGOT] > 5 x upper limit of normal; bilirubin > 3.0 mg/dL)\r\n* Forced expiratory volume in 1 second (FEV1) of < 50% predicted or diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) < 40% (patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing)Xx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) > 40% predicted, corrected for hemoglobin and/or alveolar ventilationXx_NEWLINE_xXAdjusted (Adj) carbon monoxide diffusing capability (DLCO) > 45% of predicted corrected for hemoglobinXx_NEWLINE_xXSubjects must have had recent pulmonary function test (PFT) measured for at least 3 months prior to study enrollment that show:\r\n* A decrease in % forced vital capacity (FVC) and/or % forced expiratory volume in 1 second (FEV1) ? 20% at screening compared with pre-transplant baseline\r\n* Lack of bronchodilator response on PFT testing < 12% change and < 200 ml change in FEV1 and/or FVCXx_NEWLINE_xXDiffusion capacity > 45% (adjusted for hemoglobin) as predicted by pulmonary function testingXx_NEWLINE_xXWithin 4 weeks before enrollment: Diffusion capacity > 45% (adjusted for hemoglobin) as predicted pulmonary function testingXx_NEWLINE_xXPulse oximetry with a baseline O2 saturation of >= 90% and diffusion capacity of the lung for carbon monoxide (DLCO) > 40% (corrected for hemoglobin)Xx_NEWLINE_xXSevere obstructive airway disease defined by forced expiratory volume at one second (FEV1) < 50%Xx_NEWLINE_xXAdequate pulmonary function, defined as ? grade 1 dyspnea and saturated oxygen (SaO2) >= 92% on room air; if pulmonary function test (PFT)s are performed based on the clinical judgment of the treating physician, patients with forced expiratory volume in 1 second (FEV1) >= 50% of predicted and carbon monoxide diffusing capability (DLCO) (corrected) of >= 40% of predicted will be eligibleXx_NEWLINE_xXAdequate pulmonary function, defined as ? grade 1 dyspnea and SaO2 ? 92% on room air; if PFTs are performed based on the clinical judgment of the treating physician, patients with FEV1 ? 50% of predicted and DLCO (corrected) of ? 40% of predicted will be eligibleXx_NEWLINE_xXPatients must be without evidence of unstable or decompensated myocardial disease; and must have adequate pulmonary reserve evidenced by forced expiratory volume in 1 second (FEV1) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 35% predicted; carbon dioxide partial pressure (pCO2) < 50 mm Hg and partial pressure of oxygen (pO2) > 60 mm Hg on room air arterial-blood gas (ABG)Xx_NEWLINE_xXKnown forced expiratory volume in 1 second (FEV1) or corrected carbon monoxide diffusing capability (cDLCO) < 50% of predictedXx_NEWLINE_xXPulmonary function tests within past 6 months showing diffusion capacity of the lung for carbon monoxide (DLCO) > 50% of predictedXx_NEWLINE_xXOxygen saturation >= 90% on room air; pulmonary function test (PFT)’s required only if symptomatic or prior known impairment - must have pulmonary function > 50% corrected carbon monoxide diffusing capability (DLCO) and forced expiratory volume in 1 second (FEV1) (within 28 days of study registration)Xx_NEWLINE_xXIf pulmonary function tests (PFTs) are performed, the forced expiratory volume 1 (FEV1)/forced vital capacity (FVC) must be greater than 60%Xx_NEWLINE_xXDocumented forced expiratory volume in 1 second (FEV1) less than or equal to 50% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 packs [pk]/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) > 50% predictedXx_NEWLINE_xXPatients with moderate to severe lung disease including: \r\n* Patients requiring oxygen (O2) supplementation\r\n* Patients unable to walk 50 feet without stopping to rest\r\n** Obstructive lung disease as defined by pre-transplant forced expiratory volume in one second (FEV1) =< 60% of predicted\r\n** Restrictive lung disease as defined by pre-transplant forced vital capacity (FVC) < 60% of predictedXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) > 1.0 LXx_NEWLINE_xXCorrected diffusing capacity of the lungs for carbon monoxide (DLCO) < 35% or receiving supplemental continuous oxygenXx_NEWLINE_xXSignificant chronic obstructive pulmonary disease (COPD) or other chronic pulmonary restrictive disease with pulmonary function test (PFT)’s indicating an forced expiratory volume in 1 second (FEV1) less than 50% or a carbon monoxide diffusing capability test (DLCO) less than 40% predicted for age\r\n* Note: Patients who have shortness of breath with minimal exertion or who are at risk for pulmonary disease will undergo pulmonary function testing and will not be eligible if their FEV1 is < 50% of expectedXx_NEWLINE_xXNo significant obstructive airways disease (forced expiratory volume in 1 second [FEV1] must be >= 50%) and must have acceptable diffusion capacity (corrected carbon monoxide diffusing capability [DLCO] > 50% of predicted)Xx_NEWLINE_xXCorrected carbon monoxide diffusing capability (DLCOc) >= 50%Xx_NEWLINE_xXPatients with medically inoperable stage I disease (T1 or T2a [tumor size =< 5 cm] N0M0) or selected stage IIa disease (T2 [tumor size > 5 cm but =< 7 cm] N0M0) who have poor lung function or other significant cardiovascular or other comorbidity such as diabetes are eligible. Patients with operable disease who choose to have SABR are also eligible. The standard justification for medical inoperability is based on pulmonary function and can include any of the following: baseline forced expiratory volume in 1 second (FEV1) < 50% of predicted value; diffusion capacity < 50% of predicted value; baseline hypoxemia or hypercapnia; exercise oxygen consumption < 50% of predicted value; severe pulmonary hypertension; severe cerebral, cardiac, or peripheral vascular disease; and severe chronic heart diseaseXx_NEWLINE_xXPulmonary function test (PFT) demonstrating a diffusion capacity of least 50% predicted.Xx_NEWLINE_xXForced vital capacity (FVC) >= 50% predictedXx_NEWLINE_xXClinically significant pulmonary dysfunction, as determined by medical history and physical examination; patients with a history of pulmonary dysfunction must have pulmonary function tests with a forced expiratory volume in 1 second (FEV1) >= 60% of predicted and a diffusing capacity of the lung for carbon monoxide (DLCO) >= 55% (corrected for hemoglobin)Xx_NEWLINE_xXOxygen saturation >= 90% on room air; pulmonary function tests (PFT’s) required only if symptomatic or prior known impairment - must have pulmonary function > 50% corrected diffusion capacity of the lung for carbon monoxide (DLCO) and forced expiratory volume in 1 second (FEV1)Xx_NEWLINE_xX? 18 to 74 years of age and fulfill at least one criteria associated with lack of fitness for intensive induction chemotherapy: i. Eastern Cooperative Oncology Group (ECOG) Performance status of 2 - 3; ii. Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction ? 50% or chronic stable angina; iii. Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) ? 65% or Forced Expiratory Volume in 1 second(FEV1) ? 65%; iv. Creatinine clearance ? 30 mL/min to < 45 ml/min; v. Moderate hepatic impairment with total bilirubin > 1.5 to ? 3.0 × Upper Limit of Normal (ULN); vi. Other comorbidity that the physician judges to be incompatible with conventional intensive chemotherapy which must be reviewed and approved by the study medical monitor before study enrollment.Xx_NEWLINE_xXSubject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal. NOTE: FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50% of predicted normalXx_NEWLINE_xXOxygen saturation >= 90% on room air; pulmonary function tests (PFT’s) required only if symptomatic or prior known impairment - must have pulmonary function > 50% corrected diffusion capacity of the lung for carbon monoxide (DLCO) and forced expiratory volume in 1 second (FEV1)Xx_NEWLINE_xXCarbon monoxide diffusing capability test (DLCO) (adjusted for hemoglobin) >= 50% of predicted and forced expiratory volume in 1 second (FEV-1) >= 50%Xx_NEWLINE_xXOxygen saturation >= 90% on room air; if symptomatic or prior known impairment, pulmonary function >= 50% corrected diffusing capacity of the lungs for carbon monoxide (DLCO) and forced expiratory volume (FEV)1 is required, within 14 days of study registration (within 30 days for pulmonary and cardiac assessments)Xx_NEWLINE_xXKnown chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 is <50% of predicted normal.Xx_NEWLINE_xXPulmonary dysfunction defined as:\r\n* Severe pulmonary dysfunction with (1) a hemoglobin corrected DLCO < 40% of predicted at the Baseline Screening visit, or (3) FVC < 45% of predicted Baseline Screening visit, or\r\n* Partial pressure (pO2) < 70 mmHg or pCO2 >= 45 mmHg without supplemental oxygen, or \r\n* O2 saturation < 92% at rest without supplemental oxygen as measured by forehead pulse oximeterXx_NEWLINE_xXAdequate pulmonary function with forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusion lung capacity (DLCO) (corrected for hemoglobin [Hgb]) >= 50% of the predicted valueXx_NEWLINE_xXPatients with pulmonary function test abnormalities as evidenced by a forced expiratory volume in 1 second to forced vital capacity ratio measurement (FEV1/FVC) < 70% of predicted for normality will be excludedXx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO) > 60%Xx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO) < 40% of normal or oxygen saturation (O2 Sat) < 92%Xx_NEWLINE_xXCarbon monoxide diffusing capability (DLCO) (corrected for hemoglobin), forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) > 50% predictedXx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume 1 (FEV1), forced vital capacity (FVC) > 40% predicted, and absence of oxygen (O2) requirements; for children that are not able to cooperate with pulmonary function tests (PFTs), a pulse oximetry with exercise should be attempted; if nether test can be obtained it should be clearly stated in the provider’s noteXx_NEWLINE_xXDiffusing capacity for carbon monoxide (DLCO) >= 45% predicted corrected for hemoglobinXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 30% of predicted postoperative (ppoFEV1, as if patient underwent a pneumonectomy)Xx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) > 35% predictedXx_NEWLINE_xXPulmonary function test including diffusion capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in 1 second (FEV1) and DLCO should be greater than 50% of predicted normal valueXx_NEWLINE_xXCarbon monoxide diffusing capability (DLCO) >= 40% predictedXx_NEWLINE_xXDiffusing capacity >= 45% (adjusted for hemoglobin) predicted by pulmonary function testingXx_NEWLINE_xXHemoglobin adjusted pulmonary carbon monoxide diffusing capability test (DLCO) >= 50% of predictedXx_NEWLINE_xXAdequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin and/or volume; children unable to perform pulmonary function tests (e.g., less than 7 years old) pulse oximetry of >= 92% on room airXx_NEWLINE_xXFor patients >= 8 years of age (or otherwise able to complete pulmonary function testing per established American Thoracic Society standards), diffusing capacity of the lungs for carbon monoxide (DLCO) (corrected/adjusted for hemoglobin) > 40% and forced expiratory volume in one second (FEV1) > 50% predicted (without administration of bronchodilator) and forced volume vital capacity (FVC) > 50% predictedXx_NEWLINE_xXDocumented forced expiratory volume in 1 second (FEV1) =< 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (approximately 20 packs/year within the past 2 years)\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) and carbon monoxide diffusing capability test (DLCO) >= 40% predicted (or per institutional standard)Xx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) >= 50% of predicted after correction for anemiaXx_NEWLINE_xXForced vital capacity (FVC) >= 40% of predicted value; or pulse oximetry >= 92% on room air if patient is unable to perform pulmonary function testingXx_NEWLINE_xXOxygen saturation >= 90% on room air and adjusted diffusing capacity of the lungs for carbon monoxide (DLCO) of at least 40%Xx_NEWLINE_xXAdjusted diffusion capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in 1 second (FEV1), and forced vital capacity (FVC) >= 50% of predicted value (corrected for hemoglobin)Xx_NEWLINE_xXLow likelihood of being eligible for reduced intensity conditioning HCT based on known information\r\n* Cardiac ejection fraction < 40% or symptomatic coronary artery disease or uncontrolled arrhythmia\r\n* Diffusing capacity of the lungs for carbon monoxide (DLCOc) < 40% or forced expiratory volume in 1 second (FEV1) < 50%\r\n* Estimated glomerular filtration rate (GFR) < 40 ml/min\r\n* Need for supplemental oxygen\r\n* Direct bilirubin or alanine aminotransferase (ALT) > 2 x upper limit of normal, unless these abnormalities are thought to be related to Gilbert’s disease or leukemic infiltration of hepatic parenchymaXx_NEWLINE_xXPre-treatment pulmonary function tests (PFTs), collected =< 90 days prior to enrollment, must show forced expiratory volume in one second (FEV1) > 60% of predictedXx_NEWLINE_xXPulmonary function test (PFT) demonstrating an adjusted diffusion capacity of least 50% predicted value for hemoglobin concentration (myeloablative regimen 1, reduced intensity regimen 3)Xx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) >= 40% predicted, and absence of oxygen (O2) requirements; for children that are not able to cooperate with pulmonary function tests (PFTs), a pulse oximetry with exercise should be attempted; if neither test can be obtained it should be clearly stated in the physician’s noteXx_NEWLINE_xXHave adequate pulmonary function to tolerate surgery; patients must have a diffusing lung capacity for carbon monoxide (DLCO) > 35% of predicted post operative forced expiratory volume in 1 second (FEV1) (ppoFEV1) > 35% of predictedXx_NEWLINE_xXAdequate pulmonary function, defined as Common Terminology Criteria for Adverse Events (CTCAE) grade =< 1 dyspnea and oxygen saturation (SaO2) >= 92% on room air; patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing and must have a forced expiratory volume in 1 second (FEV1) >= 50% of predicted value or diffusing capacity of the lung for carbon monoxide (DLCO; corrected) >= 40% of predicted valueXx_NEWLINE_xXPatients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing; those with a forced expiratory volume in 1 second (FEV1) of =< 65% or diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) < 40% will be excludedXx_NEWLINE_xXDiffusing capacity divided by the alveolar volume (DDLCO/VA) and forced expiratory volume (FEV) – 1.0 > 50% of predicted on pulmonary function testsXx_NEWLINE_xXPatients must have BOS as defined by the NIH consensus criteria (2014 updated criteria); to meet the criteria for BOS, all of the following must be present, in addition to at least one distinctive manifestation of cGVHD:\r\n* FEV1/vital capacity < 0.7 or the fifth percentile of predicted\r\n* FEV1 < 75% of predicted with >= 10% decline over less than 2 years; FEV1 should not correct to > 75% with albuterol, and the absolute decline for the corrected values should still remain at >= 10% from pre-transplant\r\n* Absence of infection in the respiratory tract\r\n* One of the 2 supporting features of BOS:\r\n** Evidence of air trapping by expiratory computed tomography (CT) or small airway thickening or bronchiectasis by high-resolution CT, or\r\n** Evidence of air trapping by PFTs: residual volume > 120% predicted or residual volume/total lung capacity elevated outside the 90% confidence interval\r\n* If a patient carries the diagnosis of cGVHD by virtue of organ involvement elsewhere, then only the first 3 criteria above are necessaryXx_NEWLINE_xXCorrected diffusing capacity for carbon monoxide (DLCOcorr) >= 40% predicted, and absence of oxygen (O2) requirements; for children that are not able to cooperate with pulmonary function tests (PFTs), a pulse oximetry with or without exercise should be attempted; if neither test can be obtained it should be clearly stated in the physician’s noteXx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin) > 40%Xx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) > 50%Xx_NEWLINE_xXPatients who have a significant history of pulmonary disease that necessitates the use of supplemental oxygen, is associated with dyspnea on walking one block or less, or requires inhaler therapy more than once per week will be required to undergo pulmonary function testing within 6 months of screening and will be excluded if forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), or diffusing capacity of the lungs for carbon monoxide (DLCO) is less than 65% of predictedXx_NEWLINE_xXAdequate pulmonary function defined as NO severe or symptomatic restrictive or obstructive lung disease, and formal pulmonary function testing showing an forced expiratory volume in 1 second (FEV1) >= 50% of predicted and a diffusion capacity of the lungs for carbon monoxide (DLCO) >= 40% of predicted, corrected for hemoglobinXx_NEWLINE_xXDocumented forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 packs (pk)/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 50%Xx_NEWLINE_xXForced vital capacity (FVC) >= 50%Xx_NEWLINE_xXDiffusion capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin [Hgb]) >= 50%Xx_NEWLINE_xXMust have a minimum level of pulmonary reserve defined as =< grade 1 dyspnea, pulse oxygen > 92% on room air, and carbon monoxide diffusing capability test (DLCO) >= 40% (corrected for anemia)Xx_NEWLINE_xXClinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in 1 second (FEV1) < 2.0 L or diffusion capacity of the lung for carbon monoxide (DLco) (corrected [corr] for hemoglobin [Hgb]) < 50% will be excludedXx_NEWLINE_xXDLCO (diffusing capacity of the lung for carbon monoxide) >= 45% of predicted corrected for hemoglobin, FEV-1 (forced expiratory volume at 1 second) >= 50% of predictedXx_NEWLINE_xXUnstable or severe intercurrent medical conditions such as severe heart (New York Association class 3 or 4) or lung (forced expiratory volume in 1 second [FEV1] < 50%) disease, uncontrolled diabetes mellitusXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and corrected diffusing capacity of the lungs for carbon monoxide (DLCO) >= 40%Xx_NEWLINE_xXAdequate pulmonary function as defined by forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted by pulmonary function testingXx_NEWLINE_xXIf measured, carbon monoxide diffusion capacity (DLCO) > 50%Xx_NEWLINE_xXAdequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin and/or volumeXx_NEWLINE_xXPulmonary function tests (forced expiratory volume in 1 second [FEV1] > 65% or forced vital capacity [FVC] > 65% of predicted) within 1 month of lymphodepletionXx_NEWLINE_xXOther serious medical conditions considered to represent contraindications to bone marrow transplant (BMT) (e.g., abnormally decreased cardiac ejection fraction, diffusion capacity of the lung for carbon monoxide [DLCO] < 50% predicted, patient on supplemental oxygen, acquired immune deficiency syndrome [AIDS], etc.)Xx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) and forced expiratory volume in one second (FEV1) > 60% predictedXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) >= 50% predicted after correction for hemoglobin (must be performed in patients with history of smoking or lung disease); DLCO may be omitted in patients without history of pulmonary disease if approved by the study chairXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) < 40% predictedXx_NEWLINE_xXCorrected diffusion capacity of the lung for carbon monoxide (DLCOcorr) > 50% if symptomatic or prior known impairmentXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) > 50% of the expected value (using USA-ITS-NIH [United States of America National Institutes of Health] equation) when corrected for hemoglobin (Hgb) (DLCO adjustment [Adj.])Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) > 65% of predicted measured, or diffusing capacity of the lung for carbon monoxide (DLCO) > 50% of predicted measuredXx_NEWLINE_xXDiffusing lung capacity for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) > 50%; DLCO should be corrected for hemoglobinXx_NEWLINE_xXWithin 90 days of registration: pulmonary function tests (PFTs) including forced expiratory volume in one second (FEV-1) and diffusing capacity of the lung for carbon monoxide (DLCO)Xx_NEWLINE_xXSubjects must have adequate lung function to permit surgical resection determined by pre-enrollment pulmonary function tests to include diffusing capacity of the lungs for carbon monoxide (DLCO)Xx_NEWLINE_xXPART 2: Diffusing capacity of the lung for carbon monoxide (DLCO) corrected > 60% normal\r\n* May not be on supplemental oxygenXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 50% of expected corrected for hemoglobin and/or volumeXx_NEWLINE_xXForced vital capacity (FVC) >= 50% of expected corrected for hemoglobin and/or volumeXx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin and/or volumeXx_NEWLINE_xXCarbon monoxide diffusing capability test (DLCO) or forced expiratory volume in 1 second (FEV1) < 65% predictedXx_NEWLINE_xXForced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) should be 50% or above of expectedXx_NEWLINE_xXCorrected diffusing capacity of the lung for carbon monoxide (DLCOcorr) < 40% normalXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 40% predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, the oxygen (O2) saturation > 92% on room airXx_NEWLINE_xXForced vital capacity (FVC) >= 40% predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, the O2 saturation > 92% on room airXx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO) >= 40% predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, the O2 saturation > 92% on room airXx_NEWLINE_xXDiffusion capacity of carbon monoxide (DLCO) or forced expiratory volume in one second (FEV1) > 45% predictedXx_NEWLINE_xXDocumented forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 pack [pk]/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) or forced expiratory volume in 1 second (FEV1) > 45% predictedXx_NEWLINE_xXPulmonary function tests (forced expiratory volume in 1 second [FEV1], forced vital capacity [FVC], carbon monoxide diffusing capability [DLCO] >= 40%Xx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO) < 40%Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) < 50% (corrected for hemoglobin)Xx_NEWLINE_xXOther concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol\r\n* Significant symptomatic deterioration of lung function; if clinically indicated, pulmonary function tests including measures of predicted lung volumes, diffusing capacity of the lung for carbon monoxide (DLco), oxygen (O2) saturation at rest on room air should be considered to exclude pneumonitis or pulmonary infiltratesXx_NEWLINE_xXDocumented forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 pack [pk]/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXPulmonary function tests: Forced expiratory volume in one second (FEV1) and carbon monoxide diffusion capacity (DLCO) (adjusted for Hb) >= 50% adjusted of predicted normal valueXx_NEWLINE_xXPulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) at least 45% of expected corrected for hemoglobin; children unable to perform pulmonary functions must have an oxygen saturation greater than 92% at room airXx_NEWLINE_xXCorrected diffusing capacity of the lung for carbon monoxide (DLCO) >= 50%Xx_NEWLINE_xXThe following pulmonary function tests (PFT) values in baseline:\r\n* Forced expiratory volume in one second (FEV1) > 80% predicted\r\n* FEV1/forced vital capacity (FVC) > 80%\r\n* Residual volume (RV)/total lung capacity (TLV) >= 80%Xx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) > 50% corrected for hemoglobinXx_NEWLINE_xXSignificant chronic obstructive pulmonary disease (COPD) or other chronic pulmonary restrictive disease with pulmonary function tests (PFTs) indicating a forced expiratory volume in one second (FEV1) less than 50% or a diffusion capacity of carbon monoxide (DLCO) less than 40% predicted for ageXx_NEWLINE_xXDiffusion capacity of carbon monoxide (DLCO) < 50% predicted (corrected for hemoglobin and alveolar volume)Xx_NEWLINE_xXAdequate pulmonary reserve defined as adequate airflow defined by a measured forced expiratory volume (FEV1) not less than 50% of the predicted value and adequate pulmonary reserve as evidenced by a FEV1/forced vital capacity (FVC) ratio of 65% or greaterXx_NEWLINE_xXFEV1 (forced expiratory volume in 1 second) >= 50% predictedXx_NEWLINE_xXFVC (forced vital capacity) >= 50% predictedXx_NEWLINE_xXDLCO (alveolar diffusion capacity for carbon monoxide) (corrected for hemoglobin) >= 50% of predictedXx_NEWLINE_xXDocumented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 pack [pk]/year of smoking within the past 2 years)\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXPulmonary function tests (forced expiratory volume in one second [FEV1] > 65% or forced vital capacity [FVC] > 65% of predicted) within 6 months of lymphodepletion (Turnstile II)Xx_NEWLINE_xXForced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) >= 40% within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months)Xx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) equal or greater than 50% predicted corrected for hemoglobin; for children =< 7 years of age who are unable to perform pulmonary function tests (PFT), oxygen saturation >= 92% on room air by pulse oximetryXx_NEWLINE_xXPatients must have forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registrationXx_NEWLINE_xXRANDOMIZED PHASE II (ARMS K AND L): Patients must have FEV1/FVC > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and FVC all > 50% predicted value; all pulmonary function tests must be obtained within one month prior to registrationXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) > 65%Xx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO) > 60%Xx_NEWLINE_xXPatients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing; those with a forced expiratory volume in one second (FEV1) of < 50 % of predicted will be excludedXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) (corrected) < 40% will be excludedXx_NEWLINE_xXForced expiratory volume in one second (FEV1) >= 50% of expected, corrected for hemoglobinXx_NEWLINE_xXForced vital capacity (FVC) >= 50% of expected, corrected for hemoglobinXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of expected, corrected for hemoglobinXx_NEWLINE_xXPatients requiring supplementary continuous oxygen and/or diffusion capacity of the lung of carbon monoxide (DLCO) < 40%Xx_NEWLINE_xXForced vital capacity (FVC) >= 50% of predicted value; or pulse oximetry >= 92% on room air if patient is unable to perform pulmonary function testingXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO) > 50% predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, then oxygen (O2) saturation > 92% on room airXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) >= 50% of expected, corrected for hemoglobin; for pediatric patients, if unable to perform pulmonary function tests (most children < 7 years of age), pulse oximetry >= 92% on room air by pulse oximetryXx_NEWLINE_xXDiffusion lung capacity of oxygen (DLCO) >= 50% of predicted corrected for hemoglobinXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) > 65% of predicted within 6 months of lymphodepletion (Turnstile II) orXx_NEWLINE_xXForced vital capacity (FVC) > 65% of predicted within 6 months of lymphodepletion (Turnstile II)Xx_NEWLINE_xXPulmonary function test (PFT) demonstrating a diffusion capacity of least 40% predictedXx_NEWLINE_xXActive infection or other medical condition which would preclude treatment in the opinion of the principal investigator; this would include a corrected diffusing capacity of the lungs for carbon monoxide (DLCO) of < 60% predicted or symptomatic interstitial lung diseaseXx_NEWLINE_xXForced expiratory volume in one second (FEV1) >= 50%Xx_NEWLINE_xXForced vital capacity (FVC) >= 50%Xx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) >= 50%Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) >= 50%Xx_NEWLINE_xXForced vital capacity (FVC) >= 50%Xx_NEWLINE_xXCorrected diffusion capacity of the lung for carbon monoxide (DLCO) >= 50%Xx_NEWLINE_xXAdequate lung function indicated by forced expiratory volume at 1 second (FEV1) >= 1 L is requiredXx_NEWLINE_xXPatients with any of the following pulmonary function abnormalities will be excluded: forced expiratory volume (FEV), < 30% predicted; diffusion capacity of the lung for carbon monoxide (DLCO), < 30% predicted (post-bronchodilator); oxygen saturation >= 92% on room air; arterial blood gas will be drawn if clinically indicatedXx_NEWLINE_xXAsymptomatic or if symptomatic, diffusing capacity of the lung for carbon monoxide (DLCO) > 50% of predicted (corrected for hemoglobin)Xx_NEWLINE_xXPulmonary (forced expiratory volume in 1 second [FEV1] > 60% predicted and corrected diffusion capacity of the lung for carbon monoxide [DLCOcor] > 60% predicted)Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) > 65% of predicted measured, or diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted measuredXx_NEWLINE_xXDocumented forced expiratory volume in 1 second (FEV1) =< 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (>= 20 pack-year smoking history with cessation within the past two years)\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXInadequate performance status/organ function defined by diffusing capacity of the lung for carbon monoxide (DLCO) < 50% (adjusted for hemoglobin [hgb]), cardiac function as defined below, Karnofsky performance status (KPS) < 60%Xx_NEWLINE_xXHemoglobin-adjusted diffusing capacity of carbon monoxide < 40%Xx_NEWLINE_xXFor all patients: diffusion capacity of the lungs for carbon monoxide (DLCO) > 40% predicted (corrected for hemoglobin [Hgb])Xx_NEWLINE_xXFor patients enrolled post-P/D, only: forced expiratory volume in 1 second (FEV1) >= 35% (corrected for Hgb) (Note: patients enrolled prior to P/D will have pulmonary function tests (PFTs) repeated pre-IMRT; if this criteria is not met, they will be removed from study)Xx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted corrected for hemoglobinXx_NEWLINE_xXAdequate pulmonary function with corrected diffusion capacity of carbon monoxide (DLCO) > 50% in those for whom this study can be performedXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) >= 45% of predictedXx_NEWLINE_xXPatient has diffusion capacity of the lung for carbon monoxide (DLCO) < 50% predicted or forced expiratory volume in 1 second (FEV1) < 50% of predicted, if applicableXx_NEWLINE_xXForced expiratory volume in one second (FEV1) and forced vital capacity (FVC) >= 40% of predicted; or in pediatric patients, if unable to perform pulmonary function tests due to young age, oxygen saturation > 92% on room airXx_NEWLINE_xXAdequate pulmonary function with forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin; exceptions may be allowed for patients with pulmonary involvement after discussing with Principal Investigator (PI)Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) 40% of predicted or 3 standard deviations (SD) below normalXx_NEWLINE_xXForced vital capacity (FVC) 40% of predicted or 3 SD below normalXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) 40% of predicted or 3 SD below normalXx_NEWLINE_xXForced expiratory volume in one second (FEV1) >= 50% of expected value obtained within 90 days of enrollment\r\n* Note: For children who are unable to cooperate for positron emission tomography (PFT)s, the criterion is: No evidence of dyspnea at rest, no exercise intolerance, and no requirement for supplemental oxygen therapyXx_NEWLINE_xXForced expiratory volume in one second (FEV1) >= 50%Xx_NEWLINE_xXDiffusing lung capacity for carbon monoxide (DLCO) >= 50%Xx_NEWLINE_xXPulmonary: asymptomatic or if symptomatic, diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted (corrected for hemoglobin)Xx_NEWLINE_xXForced expiratory volume in one second (FEV1), forced vital capacity (FVC), diffusion capacity of carbon monoxide (DLCO) (diffusion capacity) >= 40% predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, then oxygen (O2) saturation > 92% on room airXx_NEWLINE_xXCorrected diffusion capacity of the lungs for carbon monoxide (DLCO) < 50% of predicted, forced expiratory volume in one second (FEV1) < 50% of predicted, and/or receiving supplementary continuous oxygen; the FHCRC principal investigator (PI) of the study must approve of enrollment of all patients with pulmonary nodulesXx_NEWLINE_xXFEV1 (forced expiratory volume in the first second) >= 50% of predicted, corrected for volume and hemoglobinXx_NEWLINE_xXFVC (forced vital capacity) >= 50% of predicted, corrected for volume and hemoglobinXx_NEWLINE_xXDLCO (diffusing capacity of the lung for carbon monoxide) >= 50% of predicted, corrected for volume and hemoglobinXx_NEWLINE_xXCorrected diffusion capacity of the lung for carbon monoxide (DLCO) >= 40%Xx_NEWLINE_xXAdequate pulmonary function defined as absence of oxygen (O2) requirements and one of the following:\r\n* Diffusion lung capacity for carbon monoxide (DLCO) corrected >= 70% mm Hg\r\n* DLCO corrected between 60% - 69% mm Hg and partial pressure of oxygen (pO2) >= 70 mm Hg\r\n* DLCO corrected between 50% - 59% mm Hg and pO2 >= 80 mm Hg\r\n* Pediatric patients unable to perform pulmonary function tests must have O2 saturation > 92% on room air; may not be on supplemental oxygenXx_NEWLINE_xXPulmonary function (spirometry and corrected diffusing capacity of the lungs for carbon monoxide [DLCO]) >= 50% predictedXx_NEWLINE_xXAdequate pulmonary function defined as diffusion capacity of carbon monoxide (DLCO) > 30% predicted, and absence of oxygen (O2) requirementsXx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) > 60% by pulmonary function testXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) > 60% by pulmonary function testXx_NEWLINE_xXForced vital capacity (FVC) > 60% by pulmonary function testXx_NEWLINE_xXPatients must have no significant obstructive airways disease or resting hypoxemia (partial pressure of oxygen [PO2] < 80), and must have acceptable diffusion capacity (diffusion capacity of the lung for carbon monoxide [DLCO] > 50% of predicted)Xx_NEWLINE_xXForced expiratory volume in one second (FEV1)/forced vital capacity (FVC) >= 60% by pulmonary function test; for children who are uncooperative, no evidence of dyspnea at rest, or exercise intolerance, and must have a pulse oximetry > 94% in room airXx_NEWLINE_xXPulmonary function test and diffusion capacity of carbon monoxide (DLCO) > 50% of normalXx_NEWLINE_xXForced expiratory volume in one second (FEV1) and forced vital capacity (FVC) < 40% predictedXx_NEWLINE_xXPatients must have no significant obstructive airways disease (forced expiratory volume in one second [FEV1] must be >= 50% of predicted) and must have acceptable diffusion capacity (corrected diffusion capacity of carbon monoxide [DLCO] > 50% of predicted)Xx_NEWLINE_xXPatients with pre-existing severe restrictive pulmonary disease (forced vital capacity [FVC] less than 40% of predicted)Xx_NEWLINE_xXPulmonary function tests (forced expiratory volume in one second [FEV1] > 65% or forced vital capacity [FVC] > 65% of predicted) within 6 months of lymphodepletion (Turnstile II - Chemotherapy/Cell Infusion - Inclusion Criteria)Xx_NEWLINE_xXDiffusion capacity of carbon monoxide (DLCO)corr > 50% normalXx_NEWLINE_xXPulmonary: diffusing capacity of the lung for carbon monoxide (DLCO) > 30% predicted, and absence of oxygen (O2) requirements; for children that are not able to cooperate with pulmonary function tests (PFTs), a pulse oximetry with exercise should be attempted; if nether test can be obtained it should be clearly stated in the physician’s noteXx_NEWLINE_xXWith known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note: FEV1 testing is required for participants suspected of having COPD and participants must be excluded if FEV1 is <50% of predicted normal.Xx_NEWLINE_xXDiffusion capacity of oxygen, corrected for hemoglobin, > 50% of predictedXx_NEWLINE_xXPulmonary-forced expiratory volume in 1 second (FEV1) or carbon monoxide diffusing capability (DLco) < 40% or need for use of supplemental oxygenXx_NEWLINE_xXCriteria 7 Known chronic obstructive pulmonary disease (COPD) with a FEV1 < 50% of predicted normalXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) > 50% predicted with no symptomatic pulmonary diseaseXx_NEWLINE_xXDLCO ? 40% predicted with no symptomatic pulmonary disease. If DLCO is ?35% and < 40% and the patient is asymptomatic, a pulmonary consult is requiredXx_NEWLINE_xXPulmonary function test (PFT) demonstrating a diffusion capacity of least 45% predictedXx_NEWLINE_xXOther concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol\r\n* Significant symptomatic deterioration of lung function; if clinically indicated, pulmonary function tests including measures of predicted lung volumes, carbon monoxide diffusing capacity (DLco), oxygen (O2) saturation at rest on room air should be considered to exclude pneumonitis or pulmonary infiltratesXx_NEWLINE_xXFEV1 and corrected DLCO of 35% or > of predicted.Xx_NEWLINE_xXDLCO > 50%Xx_NEWLINE_xXRespiratory failure (defined as oxygen saturation [SaO2] < 90% on room air; partial pressure of carbon dioxide [PCO2] > 45mmHg; or forced expiratory volume in one second [FEV1] <1.0 liter).Xx_NEWLINE_xXPulmonary function tests diffusing capacity of the lungs for carbon monoxide (DLCO) (adjusted for hemoglobin) > 50% predictedXx_NEWLINE_xXSubject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% predicted normal; Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV < 50%Xx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >= 65% of predicted (patients >= 40 years old)Xx_NEWLINE_xXDocumented forced expiratory volume in 1 second (FEV1) less than or equal to 60% predicted tested in patients with:\r\n* A prolonged history of cigarette smoking (20 packs [pk]/year of smoking within the past 2 years).\r\n* Symptoms of respiratory dysfunctionXx_NEWLINE_xXClinically significant pulmonary dysfunction, as determined by medical history and physical exam. Patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in 1 second (FEV1) < 2.0 L or carbon monoxide diffusing capability (DLco) (correlation for hemoglobin [corr for Hgb]) < 75% will be excluded.Xx_NEWLINE_xXPulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) > 50% of predicted value (corrected for hemoglobin) within 3 months of registration.Xx_NEWLINE_xXCarbon monoxide diffusing capability (DLCO) corrected >= 60% normal (may not be on supplemental oxygen)Xx_NEWLINE_xXWithin 14 days of study registration (30 days for pulmonary and cardiac): oxygen saturation >= 90% on room air with no symptomatic pulmonary disease. If symptomatic or prior known impairment single breath carbon monoxide diffusing capacity (DLCOc) or >= 40%.Xx_NEWLINE_xXClinically significant pulmonary dysfunction, as determined by medical history and physical exam. Patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV1) < 60% of normal or carbon monoxide diffusing capacity (DLco) (corrected [corr] for hemoglobin [Hgb]) < 55% will be excluded.Xx_NEWLINE_xXForced expiratory volume in one second (FEV1), forced vital capacity (FVC) and carbon monoxide diffusing capacity (DLCOc) >= 50% of predicted).Xx_NEWLINE_xXSubject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal. NOTE: FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50% of predicted normalXx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO) > 40% with no symptomatic pulmonary diseaseXx_NEWLINE_xXCorrected diffusion capacity of the lung for carbon monoxide (DLCOcorr) > 50% ULNXx_NEWLINE_xXPulmonary function (diffusion capacity of the lung for carbon monoxide [DLCO]) > 40% of the expected value corrected for alveolar volume and hemoglobinXx_NEWLINE_xXPatients with any of the following pulmonary function abnormalities will be excluded: forced expiratory volume (FEV), < 30% predicted; diffusion capacity of the lung for carbon monoxide (DLCO), < 30% predicted (post-bronchodilator); partial pressure of oxygen (pO2) < 60 mm Hg or partial pressure of carbon dioxide (pCO2) >= 55 mm Hg on room air arterial blood gasXx_NEWLINE_xXPulmonary disease: forced vital capacity (FVC) < 60% predictedXx_NEWLINE_xXPulmonary disease: forced expiratory volume in 1 second (FEV1) < 60% predictedXx_NEWLINE_xXPulmonary disease: diffusion capacity of the lung for carbon monoxide (DLCO) parameters < 60% predicted (corrected for hemoglobin)Xx_NEWLINE_xX> 50% corrected diffusing capacity of the lung for carbon monoxide (DLCO), if presence of pleural effusion due to metastatic disease > 40% corrected DLCO is acceptable (within 28 days of treatment start)Xx_NEWLINE_xX> 50% forced expiratory volume of the lung in 1 second (FEV1), if presence of pleural effusion due to metastatic disease > 40% corrected FEV1 is acceptable (within 28 days of treatment start)Xx_NEWLINE_xXLung diffusion capacity >= 50%Xx_NEWLINE_xXSevere chronic obstructive lung disease, or symptomatic restrictive lung disease, or corrected diffusing capacity of the lungs for carbon monoxide (DLCO) of < 40% of predictedXx_NEWLINE_xXNormal lung function; patients who have extensive pulmonary metastases or any chronic pulmonary disease history must have pulmonary function testing demonstrating forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) > 65% of predicted valuesXx_NEWLINE_xXWithin 30 days of registration: Corrected carbon monoxide diffusing capability (DLCO) and forced expiratory volume in 1 second (FEV1), >= 60% predictedXx_NEWLINE_xXForced expiratory volume >= 1.0 L or >= 40% of predicted with or without bronchodilators by pulmonary function testingXx_NEWLINE_xXHistory of pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD) (forced expiratory volume in one second [FEV1] < 60% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with prolonged smoking history or symptoms of respiratory dysfunctionXx_NEWLINE_xXPatients with any of the following pulmonary function abnormalities: forced expiratory volume (FEV), < 30% predicted; diffusion capacity of the lungs for carbon monoxide (DLCO) < 30% predicted (post-bronchodilator); oxygen saturation less than 92% on room airXx_NEWLINE_xXHistory of pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD), (forced expiratory volume [FEV] > 60% of predicted for height and age required in patients with prolonged smoking history or symptoms of respiratory dysfunction)Xx_NEWLINE_xXPatients with pre-existing severe restrictive pulmonary disease (forced vital capacity [FVC] less than 60% of predicted)Xx_NEWLINE_xXCarbon monoxide diffusing capacity (DLCO; corrected for hemoglobin [Hgb]) >= 50% of predicted valueXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 50% of predicted valueXx_NEWLINE_xXForced expiratory vital capacity (FVC) >= 50% of predicted valueXx_NEWLINE_xXSpirometry diffusion capacity (diffusion capacity of the lung for carbon monoxide [DLCO]) >= 50%Xx_NEWLINE_xXDiffusion capacity of carbon monoxide (DLCO) >= 30% predicted, no oxygen (O2) requirementsXx_NEWLINE_xXPulmonary function: oxygen saturation >= 90% on room air and pulmonary function > 50% corrected diffusion capacity of the lung for carbon monoxide (DLCO) and forced expiratory volume in 1 second (FEV1) testing required only if symptomatic or prior known impairmentXx_NEWLINE_xXClinically significant pulmonary dysfunction, as determined by medical history and physical examination; patients with a history of pulmonary dysfunction must have pulmonary function tests with a forced expiratory volume in 1 second (FEV1) >= 60% of predicted and a diffusing capacity of the lung for carbon monoxide (DLCO) >= 55% (corrected for hemoglobin)Xx_NEWLINE_xXKnown severely impaired lung function (spirometry and diffusing capacity of the lung for carbon monoxide [DLCO] 50% or less of normal and oxygen [O2] saturation 88% or less at rest on room air)Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) >= 50% predictedXx_NEWLINE_xXForced vital capacity (FVC) (corrected for hemoglobin) >= 50% predictedXx_NEWLINE_xXCarbon monoxide diffusing capability test (DLCO) (corrected for hemoglobin) >= 50% predictedXx_NEWLINE_xXForced expiratory volume in one second (FEV1) >= 50% of predicted value (corrected to serum hemoglobin)Xx_NEWLINE_xXForced vital capacity (FVC) >= 50% of predicted value (corrected to serum hemoglobin)Xx_NEWLINE_xXDiffusing capacity for carbon monoxide (DLCO) >= 50% of predicted value (corrected to serum hemoglobin)Xx_NEWLINE_xXHistory of pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD), (forced expiratory volume of the lung in 1 second [FEV1] > 60% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with prolonged smoking history or signs, symptoms, or history of respiratory dysfunction)Xx_NEWLINE_xXHistory of pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD), (forced expiratory volume in one second [FEV1] > 60% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with prolonged smoking history or symptoms of respiratory dysfunctionXx_NEWLINE_xXWith impaired pulmonary function as evidenced by partial pressure of oxygen (pO2) < 70 mm Hg and carbon monoxide diffusing capability test (DLCO) < 70% of predicted or pO2 < 80 mm Hg and DLCO < 60% of predicted; (or, for pediatric patients unable to perform pulmonary function tests, then oxygen (O2) saturation < 92% on room air), or receiving supplementary continuous oxygenXx_NEWLINE_xXPulmonary function tests (PFT)s > 50% of predictedXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) or forced expiratory volume in 1 second (FEV1) > 45% predictedXx_NEWLINE_xXSignificant chronic obstructive pulmonary disease (COPD) or other chronic pulmonary restrictive disease with pulmonary function tests (PFTs) indicating an forced expiratory volume in 1 second (FEV1) less than 50% or a diffusion capacity of the lung for carbon monoxide (DLCO) less than 40% predicted for age; Note: patients who have shortness of breath with minimal exertion or who are at risk for pulmonary disease (e.g., chronic smokers) will undergo pulmonary function testing and will not be eligible if their FEV1 is < 50% of expectedXx_NEWLINE_xXSeverely impaired lung function as defined as spirometry and DLCO (corrected for Hgb)\n             that is <50% of the normal predicted value and/or O2 saturation <88% at rest on room\n             air.Xx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) > 50%\r\n* DLCO should be corrected for hemoglobinXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted value (corrected for hemoglobin)Xx_NEWLINE_xXOther serious medical conditions considered to represent contraindications to ASCT (e.g., abnormally decreased cardiac ejection fraction, diffusion capacity of the lung for carbon monoxide [DLCO] < 50% predicted, acquired immune deficiency syndrome [AIDS], etc.)Xx_NEWLINE_xXPulmonary function tests (forced expiratory volume in one second [FEV1] > 65% or forced vital capacity [FVC] > 65% of predicted are required) within 6 months of lymphodepletion in those who have a history of pulmonary disease that necessitates the use of supplemental oxygen, or is associated with dyspnea on walking one block or less, or requires inhaler therapy more than once per weekXx_NEWLINE_xXPulmonary function tests, including diffusion capacity of carbon monoxide (DLCO), within 6 weeks prior to registration; patients must have forced expiratory volume in 1 second (FEV1) >= 1.2 Liter or >= 50% predicted without bronchodilatorXx_NEWLINE_xXLung diffusion capacity for carbon monoxide (DLCO) > 50%, or forced expiratory volume at 1.0 seconds (FEV1.0) > 65% of predicted on pulmonary function testing (PFT) obtained within 28 days of study enrollmentXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) >= 40% of the expected value corrected for alveolar volume and hemoglobin (hgb) for reduced intensity transplant and DLCO >= 55% for myeloablative regimen; for children who are unable to cooperate for pulmonary function tests (PFTs), the criterion is, no evidence of dyspnea at rest, no exercise intolerance, and no requirement for supplemental oxygen therapyXx_NEWLINE_xXSeverely impaired lung function as defined as spirometry and diffusing capacity of the lungs for carbon monoxide (DLCO) that is < 50% of the normal predicted value and/or oxygen (02) saturation that is 88% or less at rest on room airXx_NEWLINE_xXCorrected diffusing capacity of the lung for carbon monoxide (DLCO) greater than or equal to 50% on pulmonary function testsXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), and forced vital capacity (FVC) >= 50% of predicted (corrected for hemoglobin)Xx_NEWLINE_xXAdequate pulmonary function based on the following pulmonary function tests done within 8 weeks of registration:\r\n* Forced expiratory volume (FEV)1 at least 2.0 liters; if less than 2.0 liters, the predicted post-resection FEV1 must be at least 0.8 liters \r\n* Diffusion capacity should be >= 50% predictedXx_NEWLINE_xXPatients with a diffusion capacity of the lung for carbon monoxide (DLCO) < 50% of normal orXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) < 50% of normalXx_NEWLINE_xXOther serious medical conditions considered to represent contraindications to bone marrow transplant (BMT) (e.g. abnormally decreased cardiac ejection fraction, diffusion capacity of the lung for carbon monoxide (DLCO) < 50% predicted, forced expiratory volume in one second (FEV1) < 70% predicted, acquired immune deficiency syndrome [AIDS], etc.)Xx_NEWLINE_xXPatients must have no significant obstructive airways disease (forced expiratory volume in 1 second [FEV1] must be >= 50%) and must have acceptable diffusion capacity (corrected diffusion capacity of the lung for carbon monoxide [DLCO] > 50% of predicted)Xx_NEWLINE_xXPatients with a diffusing capacity of the lung for carbon monoxide (DLCO) < 55% of normal or a forced expiratory volume in one second (FEV1) < 60% of normal, based on either NIH or United States (USA) normal rangesXx_NEWLINE_xXCorrected diffusion capacity of the lung for carbon monoxide (DLCO) > 45% of expected valueXx_NEWLINE_xXRespiratory compromise, defined as ventilation tests with diffusion capacity of the lung for carbon monoxide (DLCO) < 50%Xx_NEWLINE_xXAdequate pulmonary function with diffusing capacity of the lung for carbon monoxide (DLCO) > 50%Xx_NEWLINE_xXPoor pulmonary function: \r\n* For patients receiving a TBI based preparative regimen: forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin [Hgb]) =< 60% by pulmonary function tests (PFTs)\r\n* For patients receiving a non-TBI based preparative regimen: FEV1, FVC, and DLCO =< 50% predicted (corrected for hemoglobin) for patients who have not received thoracic or mantle irradiation\r\n* For patients who have received thoracic or mantle irradiation, FEV1 and FVC < 70% predicted or DLCO =< 50 of predicted; for children unable to perform PFTs because of developmental stage pulse oximetry =< 92% on room air (RA): no evidence of dyspnea at rest, no exercise intolerance\r\n* For children who are unable to cooperate for PFTs, required criteria are: no evidence of dyspnea at rest, no exercise intolerance, and not requiring supplemental oxygen therapyXx_NEWLINE_xXKnown chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) less than (<)50 percent (%) of predicted normalXx_NEWLINE_xXDiffusion lung capacity for carbon monoxide (DLCO) adjusted for hemoglobin >= 60% predicted, except if related to high volume metastatic GCT to the lungs, in which case there is no minimum DLCO requirement; in some cases, patients may not be able to undergo pulmonary function test (PFT) testing due to the severity of their presentation, such as those with high volume lung metastases or tumor-related pain (from large mediastinal masses, pleural disease, etc.) limiting their ability to complete PFTs; even when PFTs can be completed in these cases, patients will still be eligible if the low DLCO can be attributed directly to the patient's disease (e.g. large mediastinal mass) rather than intrinsic lung disease; since there is no minimum DLCO for these patients, under these extraordinary circumstances, this will be allowed; most patients in this situation will be expected to receive disease-stabilizing chemotherapy; an unadjusted DLCO may be used in place of the DLCO adjusted for hemoglobin in certain situations as per institutional policy; for example, MSKCC policy is to not adjust the DLCO for hemoglobin when the hemoglobin is >= 14.6 g/dL for males and >= 13.4 g/dL for females; in these cases, the unadjusted DLCO must be >= 60% predictedXx_NEWLINE_xXParticipant has known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume in 1 second [FEV1] <50% of predicted normal), persistent asthma, or a history of asthma within the last 2 years (controlled intermittent asthma or controlled mild persistent asthma is allowed)Xx_NEWLINE_xXIdiopathic interstitial pneumonia or impaired diffusion capacity of the lung for carbon monoxide (DLCO).Xx_NEWLINE_xXHas chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) 50% of predicted normalXx_NEWLINE_xXAny known uncontrolled underlying pulmonary disease by history, physical exam or if applicable pulmonary function tests (PFTs) (e.g. forced expiratory volume in 1 second [FEV1] or carbon monoxide diffusing capability [DLCO] 50% or less of predicted or oxygen [O2] saturation 88% or less at rest on room air)Xx_NEWLINE_xXPatients must have pulmonary function tests (PFTs) including forced expiratory volume in 1 second (FEV1) within 84 days prior to registration; for FEV1, the best value obtained pre- or post-bronchodilator must be >= 1.2 liters/second and/or >= 50% predictedXx_NEWLINE_xXPatients must not have any known uncontrolled underlying pulmonary disease (e.g. forced expiratory volume in 1 second [FEV1] or diffusion capacity of the lung for carbon monoxide [DLCO] 50% or less of predicted OR oxygen [O2] saturation 88% or less at rest on room air)Xx_NEWLINE_xXSymptomatic chronic obstructive lung disease, symptomatic restrictive lung disease, or corrected diffusing capacity of the lung for carbon monoxide (DLCO) of < 50% of predicted, corrected for hemoglobinXx_NEWLINE_xXDLCO > 50 percent predictedXx_NEWLINE_xXForced Expiratory Volume at one second (FEV1) > 1.2 liters; Diffusion Capacity of Lung for Carbon Monoxide (DLCO) ? 50% predictedXx_NEWLINE_xXDiffusing capacity of carbon monoxide (DLCO) corrected for hemoglobin > 50%Xx_NEWLINE_xXInadequate pulmonary function with mechanical parameters < 40% predicted (FEV1, FVC, TLC, DLCO).Xx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin) =< 50%Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) with >= 1200 cc or >= 50% predictedXx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO) < 40% (corrected), total lung capacity (TLC) < 40%, forced expiratory volume in one second (FEV1) < 40% and/or receiving supplementary continuous oxygenXx_NEWLINE_xXAdequate lung function; forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) ? 45% of predicted value as measured by spirometry; and oxygen saturation ? 90% on room airXx_NEWLINE_xXPatients must be considered a candidate for surgical resection of the primary tumor; standard justification for deeming a patient medically operable based on pulmonary function for surgical resection of non-small cell lung cancer (NSCLC) may include any of the following: baseline forced expiratory volume in 1 second (FEV1) > 40% predicted, post-operative predicted FEV1 > 30% predicted, diffusion capacity > 40% predicted, absent baseline hypoxemia and/or hypercapnia, exercise oxygen consumption > 50% predicted, absent severe pulmonary hypertension, absent severe cerebral, cardiac, or peripheral vascular disease, and absent severe chronic heart diseaseXx_NEWLINE_xXForced expiratory volume of the lung in 1 second (FEV1) >= 40% predictedXx_NEWLINE_xXForced vital capacity (FVC) >= 40% predictedXx_NEWLINE_xXCorrected diffusing capacity of the lung for carbon monoxide (DLCOc) >= 40% predicted; if DLCO is < 40%, patients will still be considered eligible if deemed safe after a pulmonary evaluationXx_NEWLINE_xXOther serious medical conditions considered to represent contraindications to ASCT (e.g., abnormally decreased cardiac ejection fraction, diffusion capacity of carbon monoxide [DLCO] < 50% predicted, etc.)Xx_NEWLINE_xXPulmonary function tests (PFTs) are required of all patients within 4 months prior to lymphodepletion; forced expiratory volume (FEV)1 and forced vital capacity (FVC) must be >= 65% predicted and diffusion lung capacity for carbon monoxide (DLCO) must be >= 50% predictedXx_NEWLINE_xXFEV1 < 65% predicted, FVC < 65% of predicted, DLCO (corrected for hemoglobin [Hgb]) < 50% predicted); pulmonary function tests (PFTs) within 4 months prior to consent for Step I will be required for patients with underlying risk factors such as smoking history > 10 pack years, or a history of pre-existing symptomatic lung disease (not including melanoma metastases to the lung)Xx_NEWLINE_xXClinically significant pulmonary dysfunction (FEV1< 65% predicted or FVC < 65% of predicted, DLCO (corrected for Hgb) < 50% predicted)Xx_NEWLINE_xXAdequate pulmonary function defined as:\r\n* No evidence of dyspnea at rest, no exercise intolerance, no chronic oxygen requirement, and room air pulse oximetry > 94% if there is a clinical indication for pulse oximetry; normal pulmonary function tests in patients who are capable of cooperating with testing (including diffusion capacity of the lung of carbon monoxide [DLCO]) are required if there is a clinical indication for determination; for patients who do not have respiratory symptoms, full pulmonary function tests (PFTs) are NOT requiredXx_NEWLINE_xXPulmonary diffusion capacity > 25% lower than normal predicted valueXx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) >= 50% of predicted value (corrected for hemoglobin) within 3 months of registrationXx_NEWLINE_xXAdequate pulmonary function with forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobinXx_NEWLINE_xXNormal pulmonary function tests (including diffusing capacity of the lungs for carbon monoxide [DLCO]) if there is clinical indication for determination (e.g. dyspnea at rest, known requirement for supplemental oxygen); Note: for patients who do not have respiratory symptoms or requirement for supplemental oxygen, pulmonary function tests (PFTs) are NOT requiredXx_NEWLINE_xXPulmonary: diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume (FEV1), forced vital capacity (FVC) ? 50% predicted by pulmonary function tests (PFTs)Xx_NEWLINE_xXSubject has known pulmonary disease with diffusion capacity of lung for carbon monoxide (DLCO) ? 65%, forced expiratory volume in the first second (FEV1) ? 65%, dyspnea at rest or requiring oxygen or any pleural neoplasm (Transient use of supplemental oxygen is allowed.)Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) and diffusion capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) >= 50% predictedXx_NEWLINE_xXPrimary tumor must be technically resectable by an experienced thoracic cancer clinician, with a reasonable possibility of obtaining a gross total resection with negative margins (potentially curative resection, [PCR]); however, patients must have underlying physiological medical problems prohibiting PCR (i.e., problems with general anesthesia, the operation, the post-operative (op) recovery period, or removal of adjacent functioning lung) or refuse surgery; deeming a patient medically inoperable based on pulmonary function for surgical resection may include any of the following: baseline forced expiratory volume in one second (FEV1) < 40% predicted; post-operative predicted FEV1 < 30% predicted; severely reduced diffusion capacity; baseline hypoxemia and/or hypercapnia; exercise oxygen consumption < 50% predicted; severe pulmonary hypertension; diabetes with severe end organ damage; severe cerebral, cardiac, or peripheral vascular disease; or severe chronic heart disease; any of these problems will qualify a patient for this trialXx_NEWLINE_xXForced expiratory volume in one second (FEV1) AND forced vital capacity (FVC) > 50% predictedXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) (corrected) > 50% predicted; if the corrected DLCO is not able to be calculated, principal investigator (PI) must be contactedXx_NEWLINE_xXKnown chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal or known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classificationXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >= 40% of predicted; or if unable to perform pulmonary function tests due to young age, oxygen saturation > 92% on room airXx_NEWLINE_xXClinically significant pulmonary dysfunction, as determined by medical history and physical exam. Patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV1) < 2.0 L or diffusion lung capacity [DLCO] corrected [corr] for hemoglobin [Hgb]) < 50% will be excluded.Xx_NEWLINE_xXDiffusing capacity for carbon monoxide (DLCO) >= 45% predicted corrected for hemoglobin; for children =< 7 years of age who unable to perform the pulmonary function test, an oxygen (O2) saturation of >= 92% on room airXx_NEWLINE_xXClinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in 1 second (FEV1) < 2.0 L or diffusion capacity of the lungs for carbon monoxide (DLCO) (corrected for Hb) < 50% will be excludedXx_NEWLINE_xXForced expiratory volume in one second (FEV1) >= 50% or diffusing capacity of the lungs for carbon monoxide (DLCO) (hemoglobin [Hb]) >= 40% of predicted, unless pulmonary dysfunction is deemed to be due to chronic GVHDXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 50% or diffusion capacity of the lung for carbon monoxide (DLCO) (hemoglobin [Hb]) >= 40% of predicted, unless pulmonary dysfunction is deemed to be due to chronic GVHD; for pediatric patients < 7 years old, pulmonary function testing will not be required; rather, pediatric patients < 7 years old who have pulmonary symptoms will be evaluated by a pulmonologistXx_NEWLINE_xXHistory of other pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD), (forced expiratory volume in 1 second [FEV1] < 60% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with prolonged smoking history or symptoms of respiratory dysfunctionXx_NEWLINE_xXPatients must not have any known uncontrolled underlying pulmonary disease or severely impaired lung function (spirometry and diffusing capacity of the lung for carbon monoxide [DLCO] 50% or less of normal and oxygen [O2] saturation 88% or less at rest on room air)Xx_NEWLINE_xXOther concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection; uncontrolled hypertension) that could cause unacceptable safety risks or compromise compliance with the protocol\r\n* Significant symptomatic deterioration of lung function; if clinically indicated, pulmonary function tests including measures of predicted lung volumes, diffusion capacity of the lung for carbon monoxide (DLco), oxygen (O2) saturation at rest on room air should be considered to exclude pneumonitis or pulmonary infiltratesXx_NEWLINE_xXParticipant has known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume in 1 second [FEV1] <50% of predicted normal), known moderate or severe persistent asthma within the last 2 years or currently has uncontrolled asthma of any classification (controlled intermittent asthma or controlled mild persistent asthma is allowed)Xx_NEWLINE_xXPatients with significant, symptomatic deterioration of lung function confirmed by spirometry, diffusion capacity of the lungs for carbon monoxide (DLCO), or resting oxygen (O2) saturationXx_NEWLINE_xXPulmonary function tests (PFTs) with diffusing capacity of the lung for carbon monoxide (DLCO) are conditional for subjects at the discretion of the physician; the required minimum standards for those who have PFTs include DLCO of 40%; those with DLCO of 40-49% must have a pulmonologist consult and assist with managementXx_NEWLINE_xXPatients who would be receiving SBRT for lung tumors who are known or suspected by the treating radiation oncologist to have compromised lung function must have a documented forced expiratory volume in 1 second (FEV1) >= 1 LXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) >= 50 % of predictedXx_NEWLINE_xXForced expiratory volume in one second (FEV-1) >= 50%Xx_NEWLINE_xXHas known chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal (note that FEV1 testing is required for subjects suspected of having chronic obstructive pulmonary disease and subjects must be excluded if FEV1 < 50% of predicted normal)Xx_NEWLINE_xXPatients who can perform pulmonary function tests will be excluded if they have a diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) of < 60% predicted; patients who are unable to perform pulmonary function tests (for example, due to young age and/or developmental status) will be excluded if the oxygen (O2) saturation is < 92% on room airXx_NEWLINE_xXParticipants must have adequate pulmonary function studies (PFTs), >= 50% of predicted on mechanical aspects (forced expiratory volume in 1 second [FEV^1], forced vital capacity [FVC]) and diffusion capacity (diffusion capacity of the lung for carbon monoxide [DLCO]) >= 50% of predicted (adjusted for hemoglobin); if the participant is unable to complete pulmonary function tests (PFTs) due to disease-related pain or other circumstances that make it difficult to reliably perform PFTs, documentation of pulmonary function adequate for transplant will occur via a CT scan without evidence of major pulmonary disease, and arterial blood gas resultsXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 50%Xx_NEWLINE_xXForced vital capacity (FVC) >= 50%Xx_NEWLINE_xXAdequate pulmonary function as assessed by diffusion capacity of the lung for carbon monoxide (DLCO) of >= 45% adjusted for hemoglobinXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) < 50% corrected for hemoglobinXx_NEWLINE_xXPatients with significant impairment of pulmonary function on account of chronic bronchitis, emphysema or chronic obstructive pulmonary disease (COPD) which has resulted in impairment of vital capacity of forced expiratory volume in one second (FEV1) to less than 75% of predicted normal valuesXx_NEWLINE_xXOther concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol\r\n* Significant symptomatic deterioration of lung function; if clinically indicated, pulmonary function tests including measures of predicted lung volumes, diffusing capacity of the lung for carbon monoxide (DLCO), oxygen (O2) saturation at rest on room air should be considered to exclude pneumonitis or pulmonary infiltratesXx_NEWLINE_xXForced expiratory volume in one second (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT), unless due to large mediastinal mass from HL; carbon monoxide diffusion capacity (DLCO), FEV1, and forced vital capacity all > 50% predicted value; Note: pulmonary function testing is not required for children < 8 years old, or for any child who is developmentally unable to comply with pulmonary function testingXx_NEWLINE_xXAsymptomatic or if symptomatic, diffusing capacity of the lung for carbon monoxide (DLCO) > 50% of predicted (corrected for hemoglobin)Xx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 50%Xx_NEWLINE_xXForced vital capacity (FVC) >= 50%Xx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) >= 40% of predicted (corrected for hemoglobin)Xx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin > 40%; and forced expiratory volume in one second (FEV1) > 50%Xx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) corrected > 60% normalXx_NEWLINE_xXSpirometry (forced expiratory volume in one second [FEV1] and forced vital capacity [FVC]) & corrected diffusing capacity of lungs for carbon monoxide (DLCO) >= 50% predicted; in small children use history and physical computed tomography (CT) scan to determine pulmonary statusXx_NEWLINE_xXSubjects with asymptomatic pulmonary function based on lung diffusion testing diffusion capacity of the lung for carbon monoxide (DLCO) test; DLCO >= 50% of predicted (corrected for hemoglobin)Xx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO) >= 30% predicted within 6 weeks prior to study enrollment; no oxygen (O2) requirementsXx_NEWLINE_xXPulmonary: asymptomatic or if symptomatic, diffusion lung capacity of carbon monoxide (DLCO) > 40% of predicted (corrected for hemoglobin)Xx_NEWLINE_xXForced vital capacity (FVC) >= 50% predictedXx_NEWLINE_xXAdequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobin and/or volume; children unable to perform pulmonary function tests (e.g., less than 7 years old) pulse oximetry of >= 92% on room airXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO)/alveolar volume (VA) and forced expiratory volume in 1 second (FEV-1.0) >= 60% of predicted on pulmonary function testsXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) >= 60% and corrected diffusion capacity of the lung for carbon monoxide (DLCO) >= 60%Xx_NEWLINE_xXPulmonary function test (PFT) demonstrating a diffusion capacity of least 50% predicted; for children =< 7 years of age who are unable to perform PFT, oxygen saturation >= 92% on room air by pulse oximetryXx_NEWLINE_xXHepatic: i. Total Bilirubin < 2.0 mg/dL (except for isolated hyperbilirubinemia attributed to Gilbert syndrome or antiretroviral therapy as specified in Appendix E) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5x the upper limit of normal. ii. Concomitant Hepatitis: Patients with chronic hepatitis B or C may be enrolled on the trial providing the above bilirubin and transaminase criteria are met. In addition, there must be no clinical or pathologic evidence of irreversible chronic liver disease, and there must be no active viral replication as evidenced by an undetectable hepatitis viral load by a PCR-based assay. c) Renal: Creatinine clearance (calculated creatinine clearance is permitted) > 40 mL/min. d) Pulmonary: Diffusing capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), or forced vital capacity (FVC) ? 45% of predicted (corrected for hemoglobin).Xx_NEWLINE_xXDiffusion lung capacity of carbon monoxide (DLCO) < 40% predictedXx_NEWLINE_xXPulmonary function > 50% corrected diffusing capacity of the lungs for carbon monoxide (DLCO)Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) testing required only if symptomatic or prior known impairmentXx_NEWLINE_xXOxygen saturation >= 90% on room air and diffusing capacity of the lung for carbon monoxide corrected (DLCOcor) >= 40%Xx_NEWLINE_xXPulmonary function of diffusing capacity of the lung for carbon monoxide (DLCO) adjusted for alveolar volume (adj/VA) and forced expiratory volume in one second (FEV1) >= 60% of normal indices for age and height unless the patient has a likely acute reversible etiology of decline and then DLCO adj/VA >= 30% of normal; pediatric patients unable to complete pulmonary function tests (PFTs) may be enrolled as per enrolling institution standard operating procedure (SOP) for recipient guidelinesXx_NEWLINE_xXOther concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol\r\n* Significant symptomatic deterioration of lung function; if clinically indicated, pulmonary function tests including measures of predicted lung volumes, diffusing capacity of the lung for carbon monoxide (DLco), oxygen (02) saturation at rest on room air should be considered to exclude pneumonitis or pulmonary infiltratesXx_NEWLINE_xXCorrected diffusion lung capacity of carbon monoxide (DLCO) < 35% or receiving supplemental continuous oxygenXx_NEWLINE_xXDiffusing capacity of carbon monoxide >= 50% of predictedXx_NEWLINE_xXPatients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:\r\n* Severely impaired lung function (as defined as spirometry and diffusing capacity of the lung for carbon monoxide [DLCO] that is 50% of the normal predicted value and/or oxygen [02] saturation that is 88% or less at rest on room air)\r\n* Any active (acute or chronic) or uncontrolled infection/disorders\r\n* Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy\r\n* Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (everolimus)\r\n* Patients who have a history of drug abuse in the 6 month period prior to receiving treatment with pasireotide or RAD001\r\n* History of, or current alcohol misuse/abuse within the past 12 months\r\n* Acute or chronic pancreatitisXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) < 40%, total lung capacity (TLC) < 40%, forced expiratory volume in one second (FEV1) < 40% and/or receiving supplementary continuous oxygenXx_NEWLINE_xXMust have adequate lung function defined within 150 days prior to registration as: (1) forced expiratory volume in 1 second (FEV1) > 30% of predicted or > 800 ml, (2) diffusing capacity of the lung for carbon monoxide (DLCO) > 30 % predictedXx_NEWLINE_xXAny serious and/or unstable pre-existing medical, psychiatric, or other condition (including lab abnormalities) that could interfere with subject safety, obtaining informed consent or compliance to study procedures; examples of such include uncontrolled diabetes, nonhealing wound, severe or uncontrolled infection, severe malnutrition, severely impaired lung function as defined as spirometry and diffusion capacity of carbon monoxide (DLCO) that is 50% of the normal predicted value and/or oxygen (02) saturation that is 88% or less at rest on room air, ventricular arrhythmias, active ischemic heart disease, chronic liver or renal disease, or active upper GI tract ulcerationXx_NEWLINE_xXDecrease in FEV1 of >= 12% from the baseline (FEV1/forced vital capacity [FVC] ratio < 0.8); NOTE: baseline may be defined as either pre- or post-transplant, as assessed by the treating physicianXx_NEWLINE_xXPulmonary: asymptomatic or if symptomatic, diffusion capacity of carbon monoxide (DLCO) > 50% of predicted (corrected for hemoglobin)Xx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) (adjusted) > 50%Xx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 1 literXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 2.0 liters or >= 75% of predicted for height and age; (pulmonary function tests [PFTs] are required for patients over 50 or with significant pulmonary or smoking history)Xx_NEWLINE_xXSubjects with clinical signs of pulmonary insufficiency must have diffusion capacity of the lung for carbon monoxide (DLCO) to be measured at >= 50% of predicted valueXx_NEWLINE_xXPulmonary function - diffusion capacity of at least 50% predicted; children unable to perform pulmonary function tests (e.g. less than 7 years old) pulse oximetry of >= 92% on room airXx_NEWLINE_xXPatients must also have a resting multi gated acquisition scan (MUGA) (preferred) or echocardiogram (ECHO) and pulmonary function tests (PFTs) with diffusing capacity of the lung for carbon monoxide (DLCO) performed before transplant and found to be acceptable according to the treating institution’s guidelines; recommended minimum standards include an ejection fraction (EF) greater than 35% and corrected DLCO greater than 35% for this less toxic regimen; if lower than this, single patient exemption may be soughtXx_NEWLINE_xXPatients with active pulmonary infection and/or pulse oximetry < 90% and a corrected diffusion capacity of the lung for carbon monoxide (DLCO) < 70% of predictedXx_NEWLINE_xXCorrected diffusion capacity of carbon monoxide (DLCO) < 35% and/or receiving supplemental continuous oxygenXx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO) > 50% of the expected value when corrected for hemoglobin (Hb), obtained within 28 days of enrollmentXx_NEWLINE_xXPulmonary function test demonstrating a diffusion capacity of least 50% predicted (myeloablative regimen 4, reduced intensity regimen 3) or at least 40% predicted (nonmyeloablative regimen 2); for children < 7 years of age who are unable to perform pulmonary function test (PFT), oxygen saturation > 92% on room air by pulse oximetryXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) < 40%, total lung capacity (TLC) < 40%, forced expiratory volume in 1 second (FEV1) < 40% and/or requiring continuous supplementary oxygen, or severe deficits in pulmonary function testing as defined by pulmonary consultant service; and the FHCRC principal investigator (PI) of the study must approve of enrollment of all patients with pulmonary nodulesXx_NEWLINE_xXPulmonary dysfunction as measured by a corrected diffusing capacity of the lung for carbon monoxide (DLCO) < 50% of predicted total lung capacity (TLC) < 30%, forced expiratory volume in 1 second (FEV1) < 30% and/or receiving supplementary continuous oxygen; the FHCRC principal investigator (PI) of the study must approve enrollment of all patients with pulmonary nodulesXx_NEWLINE_xXHistory of clinically significant pulmonary fibrosis or documented diffusing capacity of the lung for carbon monoxide <50% predictedXx_NEWLINE_xXSevere pulmonary dysfunction with a hemoglobin corrected DLCO < 30% or FVC < 40% of predicted or O2 saturation < 92% at rest without supplemental oxygenXx_NEWLINE_xXPulmonary: asymptomatic or if symptomatic, diffusing capacity of the lungs for carbon monoxide (DLCO) > 50% of predicted (corrected for hemoglobin)Xx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) > 60% and diffusion capacity of the lung for carbon monoxide (DLCO) > 50% of predicted lower limitXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >= 50% of predicted (for patients who have not received thoracic or mantle irradiation; for patients who have received thoracic or mantle irradiation, FEV1 and FVC >= 70% of predictedXx_NEWLINE_xXPulmonary function tests as follows: diffusion capacity of the lungs for carbon monoxide (DLCO) > 50% predictedXx_NEWLINE_xXCarbon monoxide diffusing capacity (DLCO) >= 50% of predicted corrected for hemoglobinXx_NEWLINE_xXPulmonary function tests (PFT)-forced expiratory volume in one second (FEV1), diffusing capacity of the lung for carbon monoxide (DLCO2), and forced vital capacity (FVC) >= 60% predicted value if clinically indicatedXx_NEWLINE_xXCorrected diffusion capacity of the lung for carbon monoxide (DLCO) equal or above 50% of expectedXx_NEWLINE_xXAbnormal lung diffusion capacity (diffusing capacity of the lungs for carbon monoxide [DLCO] < 40% predicted)Xx_NEWLINE_xXSubjects > 10 years: DLCO (diffusion capacity) > 50% of predicted (corrected for hemoglobin)Xx_NEWLINE_xXFEV1, FVC > 50% of predicted; Note: If unable to perform pulmonary tests, then O2 saturation > 92% on room air.Xx_NEWLINE_xXSignificant symptomatic deterioration of lung function; if clinically indicated, pulmonary function tests including measures of predicted lung volumes, diffusing capacity of the lung for carbon monoxide (DLco), oxygen (O2) saturation at rest on room air should be considered to exclude pneumonitis or pulmonary infiltratesXx_NEWLINE_xXPatients be able to undergo VATS resection as defined below:\r\n* Preoperative forced expiratory volume in 1 second (FEV1) >= 40% predicted OR\r\n* Post-operative predicted FEV1 >= 0.8 l\r\n* Mercury (Hg) >= 8.0\r\n* No evidence of coronary ischemia on cardiac evaluation per institutional standard (ie. cardiology evaluation, stress test, etc.)Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) of >= 1 liter and diffusion capacity of carbon monoxide (DLCO) >= 40% of predictedXx_NEWLINE_xXPulmonary function test (PFT) demonstrating a diffusion capacity of least 50% predicted, corrected for hemoglobinXx_NEWLINE_xXClinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV1) < 2.0 L or diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin [Hgb]) < 50% will be excludedXx_NEWLINE_xXForced expiratory volume in one second (FEV1) must be >= 1.0 LXx_NEWLINE_xXPatients with significant impairment of pulmonary function on account of chronic bronchitis or chronic obstructive pulmonary disease (COPD) which has resulted in impairment of vital capacity of forced expiratory volume in one second (FEV1) to less than 75% of predicted normal valuesXx_NEWLINE_xXForced expiratory volume (FEV) < 30% predictedXx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO) < 30% predicted (post-bronchodilator)Xx_NEWLINE_xXPulmonary function: > 40% corrected diffusing capacity of carbon monoxide (DLCO) and forced expiratory volume in one second (FEV1) (oxygen saturation [> 92%] can be used in child where pulmonary function tests [PFT's] cannot be obtained)Xx_NEWLINE_xXCorrected diffusing capacity of the lung for carbon monoxide (DLCOcorr) > 50% of normal, (oxygen saturation [> 92%] can be used in child where pulmonary function tests [PFT’s] cannot be obtained)Xx_NEWLINE_xXPatients with prior smoking history or emphysema will require diffusion lung capacity for carbon monoxide (DLCO) of >= 80% of predicted value for ageXx_NEWLINE_xXClinically significant pulmonary symptoms and signs, any active pulmonary or respiratory infection at enrollment, pulmonary infiltrates on screening CT scan of the chest that are associated with symptoms (including dyspnea), resting or exercise arterial oxygen saturation (SpO2) less than (<) 90 percent (%), requirement for supplementary oxygen at rest or exercise (either continuously or intermittently), moderate (40%-60% predicted) or severe (<40% predicted) decreased diffusing capacity for carbon monoxide (DLCO) or mild (>60% </= lower limit of normal [LLN]% predicted) decrease with clinically significant symptomsXx_NEWLINE_xXFEV1, FVC and corrected DLCO > 40%.Xx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) <60% of the predicted valuesXx_NEWLINE_xXPulmonary function test (PFT) demonstrating a diffusion capacity of least 50% predicted; for children =< 7 years of age who are unable to perform PFT, oxygen saturation >= 92% on room air by pulse oximetryXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) > 2.0 liters or > 75% of predicted for height and age; pulmonary function tests (PFTs) are required for patients over 50 years old or with significant pulmonary or smoking historyXx_NEWLINE_xXForced vital capacity (FVC), forced expiratory volume in one second (FEV1) or diffusion capacity of carbon monoxide (DLCO) > 50% predicted- before admission for transplant as per institutional standards; patients on home oxygen are not allowed on the protocolXx_NEWLINE_xXGreater than or equal to (>=) 75 years of age or >= 65 up to 75 years of age and have at least one of the following: congestive heart failure or ejection fraction less than or equal to (<=) 50 percent; creatinine greater than (>) 2 milligram per deciliter (mg/dL); dialysis or prior renal transplant; documented pulmonary disease with lung diffusing capacity for carbon monoxide (DLCO) <= 65 percent of expected, or forced expiratory volume in 1 second (FEV1) <= 65 percent of expected or dyspnea at rest requiring oxygen; eastern cooperative oncology group (ECOG) performance status of 2; prior or current malignancy that does not require concurrent treatment; unresolved infection; comorbidity that, in the Investigator's opinion, makes the participant unsuitable for intensive chemotherapy and must be documented and approved by the Sponsor before randomizationXx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) >= 40%Xx_NEWLINE_xXForced expiratory volume (FEV) =< 1.2 L/sXx_NEWLINE_xXForced vital capacity (FVC) >= 40% of predicted value; or pulse oximetry >= 92% on room air if patient is unable to perform pulmonary function testingXx_NEWLINE_xXHistory of other pulmonary disease such as emphysema or chronic obstructive pulmonary disease, (forced expiratory volume in one second [FEV1] < 60% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with prolonged smoking history or symptoms of respiratory dysfunctionXx_NEWLINE_xXForced vital capacity (FVC) >= 50% of predicted value or pulse oximetry (Pox) >= 92% on room airXx_NEWLINE_xXForced expiratory volume of the lung in one second (FEV1) > 40% of predicted at the screening visitXx_NEWLINE_xXForced vital capacity (FVC) > 40% of predicted at the screening visitXx_NEWLINE_xXForced expiratory volume in one second (FEV1) >= 50% of expected corrected for hemoglobinXx_NEWLINE_xXForced vital capacity (FVC) >= 50% of expected corrected for hemoglobinXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of expected corrected for hemoglobinXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) > 50% of predicted and diffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of predictedXx_NEWLINE_xXForced expiratory volume in one second (FEV1), forced vital capacity (FVC), and adjusted diffusing capacity of the lungs for carbon monoxide (DLCO) >= 50% of predicted values on pulmonary function testsXx_NEWLINE_xXCurrent severely impaired lung function (i.e., forced expiratory volume in 1 second [FEV1] < 1 liter)Xx_NEWLINE_xXChest x-ray (CXR) or computed tomography CT within 4 weeks prior to Day 1 with no evidence of pulmonary congestion, pleural effusions, pulmonary fibrosis, or significant emphysema. If results are questionable, patients should have additional lung function testing to exclude clinically relevant restriction or obstruction. Patients must have a forced expiratory volume (FEV-1) and Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) of at least 65% and 50% of expected, respectively.Xx_NEWLINE_xXDiffusion capacity of carbon monoxide (DLco) <50% of predicted (corrected for hemoglobin).Xx_NEWLINE_xXNo history of pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD), (forced expiratory volume in one second [FEV1] > 2L or >= 50% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with significant pulmonary or smoking historyXx_NEWLINE_xXForced vital capacity (FVC) >= 40% of predicted value; or pulse oximetry >= 92% on room air if patient is unable to perform pulmonary function testingXx_NEWLINE_xXPatient pulmonary function showed that pre-bronchial dilator FEV1 < 25% or diffusing capacity of the lung for carbon monoxide (DLCO) < 25%Xx_NEWLINE_xXRecipient must have adequate pulmonary function defined as NO severe or symptomatic restrictive or obstructive lung disease, and formal pulmonary function testing showing an FEV1 >50% (predicted) and a DLCO >40% (predicted), corrected for hemoglobin.Xx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 40% of predictedXx_NEWLINE_xXForced vital capacity (FVC) >= 40% of predictedXx_NEWLINE_xXForced expiratory volume (FEV) 1 > 2.0 liters or > 75% of predicted for height and age (pulmonary function test [PFTs] are required for patients over 50 years old or with significant pulmonary or smoking history)Xx_NEWLINE_xXDiffusion capacity of the lung for carbon monoxide (DLCO)/DLCO corrected for alveolar volume (VA) and forced expiratory volume in one second (FEV-1.0) > 50% of predicted on pulmonary function testsXx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) >= 45% predicted corrected for hemoglobin; for pediatric patients, if unable to perform pulmonary function, >= 92% oxygen saturation with pulse oximetryXx_NEWLINE_xXAdequate pulmonary function with forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) at least 45% of expected corrected for hemoglobin; children unable to perform pulmonary functions must have an oxygen saturation greater than 92% at room airXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) > 50% of expected value (hemoglobin [Hb] corrected), obtained within 28 days of enrollmentXx_NEWLINE_xXForced expiratory volume in one second (FEV1), forced vital capacity (FVC) and corrected diffusing capacity of the lung for carbon monoxide (DLCO) >= 50% predictedXx_NEWLINE_xXPulmonary: Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and carbon monoxide diffusing capacity (DLCO) (corrected for Hb) greater than 50% predicted; for patients in which pulse oxymetry is performed, O2 saturation greater than 92%Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) and forced vital capacity (FVC) > 60% predicted by pulmonary function test; for children who are unable to do pulmonary function tests (PFTs), no evidence of dyspnea at rest and no exercise intolerance should be documented; note: the pulmonary function test must be performed within 4 weeks prior to enrollmentXx_NEWLINE_xXForced expiratory volume (FEV)1, forced vital capacity (FVC) and carbon monoxide diffusing capability (DLCO) (corrected for hemoglobin [Hgb]) >= 50%Xx_NEWLINE_xXPatients must have adequate pulmonary reserve evidenced by predicted post-operative forced expiratory volume in 1 second (FEV1) and diffusion capacity of the lung for carbon monoxide (DLCO) equal to or greater than 40% predicted; partial pressure of carbon dioxide measurement (pCO2) less than 50 mm Hg and partial pressure of oxygen measurement (pO2) greater than 60 mm Hg on room air arterial blood gas measurement (ABG); and be on no immunosuppressive medications except inhaled corticosteroidsXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >= 40% predicted, corrected diffusion capacity of the lung for carbon monoxide (DLCOc) >= 40% predictedXx_NEWLINE_xXForced expiratory volume in one second (FEV1) >= 40%; no symptomatic pulmonary diseaseXx_NEWLINE_xXForced vital capacity (FVC) >= 40%; no symptomatic pulmonary diseaseXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) >= 40%; no symptomatic pulmonary diseaseXx_NEWLINE_xXPulmonary function tests (PFTs) with diffusing capacity of the lung for carbon monoxide (DLCO) within 90 days prior to registrationXx_NEWLINE_xXPatient at high-risk of complications from lobectomy meeting a minimum of one major criteria or two minor criteria as described below:\r\n* Major criteria\r\n** Predicted postoperative forced expiratory volume in one second (FEV1) =< 40%\r\n** Predicted postoperative DLCO =< 40%\r\n** Age >= 72\r\n* Minor criteria\r\n** Predicted postoperative FEV1 41-60%\r\n** Predicted postoperative DLCO 41-60%\r\n** Pulmonary hypertension (defined by a pulmonary artery systolic pressure greater than 40 mm Hg) as estimated by echocardiography or right heart catheterization\r\n** Poor left ventricular function (defined as an ejection fraction 40% or less)\r\n** Resting or exercising arterial partial pressure of oxygen (pO2) =< 55 mmHg or oxygen saturation (SpO2) =< 88%\r\n** Partial pressure of carbon monoxide (pCO2) > 45 mm Hg\r\n** Modified Medical Research Council Dyspnea Scale >= 3Xx_NEWLINE_xXHistory of severe chronic obstructive pulmonary disease (COPD) defined as a forced expiratory volume in 1 second (FEV1) < 50% of predictedXx_NEWLINE_xXHas a pre-treatment pulmonary function test (PFT) showing an carbon monoxide diffusing capability (DLCO) adjusted for hemoglobin of less than 60%Xx_NEWLINE_xXAdjusted diffusion capacity of the lung for carbon monoxide (DLCO) < 60%Xx_NEWLINE_xXSubjects with evidence of underlying obstructive pulmonary disease prior to transplant (clinical history of asthma or baseline forced expiratory volume in 1 second [FEV1] < 80% predicted with FEV1/forced vital capacity [FVC] < 80%)Xx_NEWLINE_xXAdvanced pulmonary disease as assessed by clinical symptoms of shortness of breath or known forced expiratory volume in 1 second (FEV1) < 1Xx_NEWLINE_xXForced expiratory volume in one second (FEV1) and forced vital capacity (FVC) >= 40% of predicted; or if unable to perform pulmonary function tests due to young age, oxygen saturation > 92% on room airXx_NEWLINE_xXPatients with severe chronic obstructive pulmonary disease (COPD) defined as a forced expiratory volume in one second (FEV1) < 50%Xx_NEWLINE_xXALS PATIENTS: Must have ALSFRS-R walking score of at least 3 or 4 and forced vital capacity (FVC) at least 50% (to ensure patients are fit enough for ambulation and physical activity)Xx_NEWLINE_xXSevere obstructive lung disease (forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] < 70% post bronchodilator and forced expiratory volume in 1 second < 30% predicted)Xx_NEWLINE_xXFEV1 (forced expiratory volume in 1 second) >= 50% predictedXx_NEWLINE_xXFVC (forced vital capacity) >= 50% predictedXx_NEWLINE_xXDLCO (diffusing capacity of the lung for carbon monoxide) (corrected for hemoglobin) >= 50% of predictedXx_NEWLINE_xXPulmonary: asymptomatic or if symptomatic, diffusing capacity of the lung for carbon monoxide (DLCO) > 60% of predicted (corrected for hemoglobin)Xx_NEWLINE_xXDiffusing capacity for carbon monoxide (DLCO) adjusted for hemoglobin or forced vital capacity (FVC) > 50% predictedXx_NEWLINE_xXPulmonary disease with forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) or diffusion capacity of the lung for carbon monoxide (DLCO) parameters < 45% predicted (corrected for hemoglobin) or requiring supplemental oxygen; children who are developmentally unable to perform pulmonary function testing will be assessed solely on their need for supplemental oxygenXx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) (corrected for hemoglobin), forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >= 50% predictedXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) >= 50% or diffusion capacity of the lung for carbon monoxide (DLCO) (hemoglobin [Hb]) >= 40% of predicted, unless pulmonary dysfunction is deemed to be due to chronic GVHDXx_NEWLINE_xXForced vital capacity (FVC) or forced expiratory volume of the lung in 1 second (FEV1) >= 40% predictedXx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide to alveolar volume (DLCO/VA) > 40%Xx_NEWLINE_xXA forced expiratory volume in one second (FEV1) of 60% or greater, a diffusion capacity of 50% or greater, and a oxygen partial pressure (PO2) of 80 mm mercury (Hg) or greater on pulmonary function testingXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) > 800 ccXx_NEWLINE_xXPulmonary function test including diffusing capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in 1 second (FEV1) and DLCO should be greater than 50% of predicted normal valueXx_NEWLINE_xXCorrected diffusing capacity of the lungs for carbon monoxide (DLCOcorr) > 40% normalXx_NEWLINE_xXPulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) ? 50% (adjusted for hemoglobin), and forced expiratory volume in one second (FEV1) or forced vital capacity (FVC) ? 50%; for children who are unable to perform for Pulmonary Function Tests (PFTs) due to age or developmental ability, there must be no evidence of dyspnea and no need for supplemental oxygen, as evidenced by O2 saturation ? 92% on room air.Xx_NEWLINE_xXChronic obstructive pulmonary disease (COPD), Global Initiative for Chronic Obstructive Lung Disease (GOLD) II or greater (defined as forced expiratory volume in 1 second [FEV1]/ forced vital capacity [FVC] < 70% and FEV1 % predicted < 80%)Xx_NEWLINE_xXDiffusing capacity of the lung for carbon monoxide (DLCO) > 40% predicted, corrected for hemoglobin and/or alveolar ventilationXx_NEWLINE_xXCarbon monoxide diffusing capability test (DLCO) >= 50% (adjusted for hemoglobin) and forced expiratory volume in 1 second (FEV1) >= 50%Xx_NEWLINE_xXForced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and adjusted diffusion capacity of the lung for carbon monoxide (DLCO) must be >= 50% of predicted valuesXx_NEWLINE_xXForced expiratory volume 1 (FEV1), forced vital capacity (FVC), and adjusted diffusing capacity of the lungs for carbon monoxide (DLCO) >= 50% of predicted values on pulmonary function testsXx_NEWLINE_xXCarbon monoxide diffusing capability test (DLCO) > 60% predicted and in children- room air oxygen saturation > 92%Xx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO) >= 50% of predicted (corrected for hemoglobin)Xx_NEWLINE_xXForced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and diffusion capacity of the lung for carbon monoxide (DLCO) adjusted >= 50% of predicted values on pulmonary function testsXx_NEWLINE_xXForced expiratory volume at one second (FEV1): best value obtained pre- or post-bronchodilator must be ? 1.0 liters/second or > 50% predicted valueXx_NEWLINE_xXCorrected diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% by pulmonary function testXx_NEWLINE_xXCorrected DLCO > 40% by pulmonary function testXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted values on pulmonary function testsXx_NEWLINE_xXCorrected diffusion capacity of the lung for carbon monoxide (DLCO) < 40% of predicted, total lung capacity (TLC) < 30% of predicted, forced expiratory volume in one second (FEV1) < 30% of predicted, or receiving continuous supplementary oxygenXx_NEWLINE_xXDiffusing capacity for carbon monoxide (hemoglobin corrected DLCO) < 50% predictedXx_NEWLINE_xXSpirometry (FEV1 and forced vital capacity [FVC]) ?80% of predicted valueXx_NEWLINE_xXDiffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) >= 40% predicted, and absence of oxygen (O2) requirementsXx_NEWLINE_xXPatients must have adequate pulmonary function: forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) at least 60% predicted value by spirometryXx_NEWLINE_xXDiffusing capacity for carbon monoxide (DLCO) < 50% predictedXx_NEWLINE_xXForced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) >= 50% predicted, corrected carbon monoxide diffusing capability test (DLCO) >= 40% predictedXx_NEWLINE_xXSubjects with adequate physical function as measured by:a)Cardiac: Left ventricular ejection fraction at rest must be >35%, or shortening fraction > 25%. b)Hepatic: Bilirubin < 2.5 mg/dL; and ALT, AST, and Alkaline Phosphatase < 5 x ULN. c)Renal: Serum creatinine within normal range for age, or creatinine clearance or GFR > 40 mL/min/1.73m2. d)Pulmonary: FEV 1, FVC, DLCO (diffusion capacity) > 50% predicted (corrected for hemoglobin); or 02 saturation > 92% on room air.Xx_NEWLINE_xXPatients with poor lung function (forced expiratory volume in one second [FEV1]% < 50% or diffusion capacity of carbon monoxide [DLCO] < 50% predicted or home oxygen requirement) and lung lesions undergoing non-anatomic lung resection (i.e. wedge resection) ORXx_NEWLINE_xXAt least one of the following:\r\n* Mild or worse sputum cytologic atypia\r\n* Endobronchial dysplasia (score >= 4) on a previous bronchoscopy.\r\n* At least mild airflow limitation on pulmonary function testing (forced expiratory volume in one second [FEV1]/forced vital capacity [FVC] < 70% actual)Xx_NEWLINE_xXCOPD, defined as forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) < 70% and FEV1% predicted < 80%Xx_NEWLINE_xXPulmonary function: carbon monoxide diffusing capability test (DLCO) >= 40% (adjusted for hemoglobin) and forced expiratory volume in 1 second (FEV1) >= 50%Xx_NEWLINE_xXPulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) ? 40% (adjusted for hemoglobin) and forced expiratory volume in one second (FEV1) ? 50%Xx_NEWLINE_xXSubject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% predicted normal; Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50%Xx_NEWLINE_xXPatients receiving SBRT lung treatment and who have any one of the following high risk features:\r\n* Lung lesion > 5 cm\r\n* Diffusing capacity of the lungs for carbon monoxide (DLCO) < 35%\r\n* Forced expiratory volume, first second (FEV1) < 0.5 L\r\n* Central lung tumors (defined as within 2 cm from the proximal bronchial tree)\r\n* Tumors that abut the great vessels, trachea, spinal cord, or esophagus\r\n* Prior lobectomy or pneumonectomy\r\n* Prior lung radiation (SBRT or conventional definitive lung radiation)Xx_NEWLINE_xXCarbon monoxide diffusing capability (DLCO) > 60% (hemoglobin adjusted) by pulmonary function test (PFT)sXx_NEWLINE_xX